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Abstract

Background: Increased oxidative stress, inflammatory responses and mitochondrial
dysfunction have been implicated in diabetes, obesity (diabesity) and cardiovascular
diseases. Type 2 diabetes is the most common metabolic disorder, characterized by
insulin resistance and pancreatic islet β-cell failure. The most common complications
associated

with

type

2

diabetes

are

hyperinsulinemia,

hyperglycemia,

hyperlipidemia/dyslipidemia, increased inflammatory and reduced insulin response.
Aspirin (ASA) and other non-steroidal anti-inflammatory drugs (NSAIDs) have been
associated with the prevention of diabetes, obesity and related cardiovascular
disorders. Aspirin has been used in many clinical and experimental trials for the
prevention of diabetes and associated complications. Aims and hypothesis: Since
inflammation, oxidative stress and mitochondrial dysfunction are hallmarks of many
degenerative diseases, including diabetes, and aspirin and other NSAIDs have been
used in clinical trials for the prevention of diabetes and related complications, we
hypothesize that ASA might be involved in altering the molecular and metabolic
targets affected in type 2 diabetes.

Thus our main aim was to elucidate the

mechanism of aspirin action in the pathophysiology and progression of disease using
an experimental rat model for type 2 diabetes. Methods: In this study, five month
old Goto-Kakizaki (GK) rats, which showed signs of hyperglycemia were used. Two
subgroups of GK and Wistar control rats were injected intraperitoneally with 100 mg
aspirin/kg/body weight/day for 5 weeks. Animals were sacrificed and blood and
tissues were collected after performing glucose tolerance (2 h post 2g IP glucose
ingestion) tests in experimental and control groups.

Results: Aspirin caused a

decrease in hyperglycemia which was accompanied by a significant improvement in
glucose tolerance after ASA treatment in GK rats compared to the nondiabetic
Wistar rats. Also, the ASA treated GK rats exhibited a significant decrease in
insulinemia. ASA treatment caused a marked reduction in the pro-inflammatory
prostaglandin, PGE2, which was significantly higher in GK rats. Aspirin treatment
also improved energy metabolism in peripheral tissues. On the other hand, no
significant organ toxicity was observed after ASA treatment at this dose and time
period. However, the total cholesterol and lipoprotein levels were significantly

viii

increased in GK rats, which decreased after ASA treatment. Immunofluorescence
staining for insulin/glucagon secreting pancreatic cells showed improved β-cell
structural and functional integrity in ASA-treated rats which was also confirmed by
SDS-PAGE and Western blot analysis. Conclusion: The improved glucose tolerance
in ASA-treated GK rats may be associated with increased insulin responses due to
the anti-inflammatory properties of ASA and improvements in ROS/RNS –
dependent (oxidative stress related) alterations in mitochondrial functions which
facilitated insulin signaling and energy utilization in target tissues. These results may
have implications in determining the therapeutic use of ASA in insulin-resistant type
2 diabetes. Significance: Since the UAE is one of the fastest growing countries
where type 2 diabetes is prevalent, our study could help in identifying the metabolic
targets affected in diabetes and after treatment with aspirin. The study might be
significant in designing therapeutic strategies and in the management of this chronic
disease.

Keywords: Type 2 diabetes mellitus (T2DM), insulin resistance, insulin signaling,
metabolic alterations, aspirin (ASA), oxidative stress, energy metabolism.
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)Title and Abstract (in Arabic

تأثيرات األسبرين على التغيرات االستقالبية في النوع الثاني لداء السكري

الملخص
تسببت زيادة االكسدة  ،واالستجابات االلتهابية و ضعف الميتوكوندريا في مرض السكري  ،والسممةة
 ) diabesityو أمراض القلب واألوعيمة الدمويمةا السمكري ممن الةمو  2همو اضماراا التمليمل الئم األي األكلمر
شيوعا  ،والتي تتميز بمقاوممة األنسمولين و ف مل ا يما بيتما جزيمرة فمي البةكريما

ا المفماعاات األكلمر شميوعا

المرتباة بداء السكري من الةو  2و فرط ،ارتاما السمكر فمي المدل والمدهوض ر اضماراا شممول المدل  ،وزيمادة
التهابات وانخاماض اسمتجابة األنسمولين ا االسمبرين  ) ASAوغيرهما ممن العقما ير غيمر السمتيرويدية المفمادة
ل لتهابممات المسممكةات ) ارتباممت مممو الو ايممة مممن مممرض السممكري  ،والسمممةة واضممارابات القلممب واألوعيممة
الدمويممة تات الةمملةا و ممد اسممتخدل االسممبرين فممي العديممد مممن التجممارا السممريرية والتجريبيممة للو ايممة مممن مممرض
السكري والمفاعاات المةاحبة
األهداف و الارضية :مة االلتهاا واإلجهاد التأكسدي و ضعف الميتوكونمدريا همي السممات المميمزة
كلير من األمراض التةكسية  ،بما في تلك مرض السكري  ،واألسمبرين و مفمادات االلتهماا غيمر السمتيروأليدية
األارى التمي اسمتخدمت فمي التجمارا السمريرية للو ايمة ممن ممرض السمكري و مفماعااتف  ،ونممن ناتمرض أض
 ASAد يكموض متورطما فمي تئييمر أهمداف جزي يمة و التمليمل الئم األي تتمأفر فمي ممرض السمكري ممن الةمو  2ا
وهك ا كاض هدفةا الرأليسي لتوضمي لليمة عممل األسمبرين فمي الايزيولوجيما المرضمية و تامور الممرض باسمتخدال
نموتج الا راض التجريبية لمرض السكري من الةو 2
الطريقة :في ه ه الدراسة ،تم استخدال الا راض عمر امسة أشهر) ، (GKوالتي أظهرت ع مات على
ارتامما السممكر فممي الممدل الجلوكمموز دمماألم فممي الممدل  95-80ملمم /ر ديسمميلتر مقابممل  60-55ملمم /ر ديسمميلتر ف ممراض
ويستار سليمف)ا تم حقن مجموعتين فرعيتين من  GKوجرتاض ويستار سليمف البريتونى ممو  100ملم /األسمبرين
ر كمم /ر وزض الجسممم ر يممول ,لمممدة  5أسممابيوا تمممت التفمممية بالميوانممات .جمممو الممدل واألنسممجة بعممد اداء تممممل
الئلوكوز  2ساعة بعد حقن  G IP2الجلوكوز االبت

) ااتبارات في المجموعتين الفاباة والتجريبيةا

النتائج  :تسبب األسبرين انخااض في ارتاا السمكر فمي المدل والم ي كماض يرافقمف تمسمن كبيمر فمي تمممل
الئلوكوز بعد الع ج  ASAفي الا راض  GKبالمقارنة مو الا راض ويستار غير مةابين بالسكرا أيفا ،أظهمرت
الا راض  GK ASAتعامل انخااضا كبيرا في األنسمولين فمي المدلا تسمببت المعاملمة  ASAانخاماض ملمموظ فمي
البروسممتاج ندين المواليممة ل لتهابممات ،PGE2 ،ال م ي كمماض أعلممى ب ممكل ملممموظ فممي الا ممراض GKا تمسممن دواء
األسبرين أيفا استق ا الاا ة في األنسجة الارفيةا ممن ناحيمة أامرى ،لمم ي حمس أي سممية الجهماز كبيمرة بعمد
العم ج  ASAفمي هم ه الجرعمة والاتمرة الزمةيمةا ومممو تلمك ،فقمد ارتامو مجممالي الكولسمترو والبمروتين الممدهةي
المستويات ب كل ملموظ في الا راض  ،GKوالتي انخافت بعد الع ج ASAا أظهر المةماعي تلاميل لسنسمولين
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ر الجلوكمماجوض مفممراز ا يمما البةكريمما

وتمسممين ا يمما بيتمما الس م مة الهيكليممة والوظيايممة فممي الا ممراض المعالجممة

-ASAوهو ما أكده أيفا  SDS-PAGEوتمليل لاخة غربيةا
الخالصة :تمسمن سمكر المدل فمي الا مراض  GKتعاممل  -ASAمد تترافمم ممو زيمادة اسمتجابات األنسمولين
نظممرا لخةمماألا مفممادة ل لتهابممات مممن  ASAوالتمسمميةات فممي  ROS / RNSمعتمممد علممى االكسممدة تات
الةمملة) تئيممرات فممي وظمماألف الميتوكونممدريا التممي سممهلت مشممارات األنسممولين و اسممتخدال الاا ممة فممي األنسممجة
المسممتهدفةا ممد يكمموض له م ه الةتمماألت لفممار فممي تمديممد االسممتخدال الع جممي لممل ASAفممي مممرض السممكري مقاومممة
لسنسولين من الةو 2ا
االهمية :اإلمارات العربية المتمدة هي واحدة من أسر البلداض نموا فمي نمو  2ممن ممرض السمكري ،
يمكن أض تساعد دراستةا في تمديد اهداف األيض التي تتأفر بمرض السكري وبعد الع ج مو األسبرينا د تكوض
ه ه الدراسة هامة في تةميم االستراتيجيات الع جية وفي مدارة ه ا المرض المزمنا
مفاااهيا الب اار الرئيسااية :داء السممكري مممن الةممو  ، ) T2DM 2مقاومممة األنسممولين  ،مشممارات األنسممولين ،
تعدي ت التمليل الئ األي  ،األسبرين  ، ) ASAاالكسدة  ،والتمليل الئ األي للاا ة ا
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Chapter 1: Introduction

1.1 Overview
Diabetes mellitus (DM), the most widespread complex metabolic disorder
among the world‘s population, is affecting millions of people globally.

The

prevalence is increasing rapidly. A recent study by Guariguata et al. representing 130
countries reported in 2013 that 382 million people were diabetic and this number was
expected to rise to 592 million by 2035 (1). Furthermore, there were a number of
undiagnosed cases of diabetes mellitus and impaired glucose tolerance, which could
further increase leading to higher numbers of people suffering from diabetesassociated vascular and metabolic complications (2). Similarly, the prevalence of
diagnosed and undiagnosed diabetes, generally associated with obesity, is increasing
in the Middle-East region. Almost one in 20 people suffer from diabetes in the
United Arab Emirates and this number is among the highest worldwide (3).

Apart from hyperglycemia, dyslipidemia and glycosylated hemoglobin
(Hb1ac), there are a number of biomarkers being used to elucidate the chronic
complications of diabetes. The main pathophysiological complications of diabetes
are considered to be associated with hyperglycemia, hyperlipidemia, and insulin
resistance and may include cardiomyopathy, retinopathy, nephropathy, urinary tract
infections and other metabolic complications (4).

The diagnosis and classification of diabetes has evolved over time and has
been revised due to challenges in the etiological, diagnostic and pathophysiological
complications (5). The classification system of type 1, type 2 are mainly based on
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etiological factors still presents challenges due to the presence of additional causative
factors, therefore a number of subgroups under the different types of diabetes have
also been suggested (5-7).
American Diabetes Association has come up with a new classification system
for diabetes based on a β-cell-centric classification scheme that excludes inherent and
unnecessary confusion (8). Although still popular as type 1 (previously, insulindependent diabetes mellitus) or type 2 (insulin-independent diabetes mellitus) there
is an urgent need to review the current classification system towards the consensus
on a more useful and unified system.
1.2 Type 1 diabetes
Type 1 diabetes (T1DM) accounts for 5–10% of the diabetic population. It
results from a cellular mediated autoimmune destruction of the β-cells of the
pancreas that leads to absolute insulin deficiency. The pathogenesis of T1DM is
known to include recruitment of CD4+ helper and CD8+ killer T lymphocytes and
infiltration of macrophages, which lead to inflammatory cytokine-dependent islet
destruction.
(9). Antibodies against insulin secreting cells, including those against insulin,
glutamic acid decarboxylase (GAD) and against the whole islet cell involved in the
development of T1DM can be detected at birth or in infancy (10). Markers of this
immune destruction of the cell include islet cell autoantibodies, autoantibodies to
insulin, autoantibodies to glutamic acid decarboxylase (GAD65), and autoantibodies
to tyrosine phosphatase IA2. These autoantibodies are present in 85-90 % of the
patients. The disease seems to rapidly progress in infants and children, whereas in
adults, it takes a longer time to progress (11). Children who are overweight (higher
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BMI) are more prone to develop the disease (12-14). T1DM is characterized by total
insulin absence, or very low insulin levels resulting in hyperglycemia and
ketoacidosis (15).
The symptoms generally associated with the disease include frequent
urination (polyuria) due to the osmotic effect of excess glucose in the urine, drinking
plenty of water (polydipsia), muscle cramps due to electrolyte disturbance, blurred
vision and weight loss. Excessive fluid loss leads to dehydration (16).

1.3 Type 2 diabetes
Until a few years ago type 2 diabetes (non-insulin dependent) was considered
a less complicated type of disease. This idea has changed since type 2 diabetes
mellitus (T2DM) shortened life expectancy of patients; and is also a leading cause of
premature death due to its complications which include cardiovascular disease,
blindness, amputations, and renal insufficiency. The major causes of T2DMM and
the most understood are insufficient β-cells response to insulin resistance and
decrease in its peripheral action. Genetic and environmental factors are the major
causes of T2DM.
The prevalence of T2DM has been increasing steadily all over the world. As
a result of this trend, it has become an epidemic in some countries due to the
increased number of people affected. T2DM increases with ageing, population,
smoking, and high calorie diet intake, thereby adding to the already existing burden
for healthcare providers, especially in under developed countries (1, 3, 17).

Pollution and high levels of environmental toxins are also related to the
development of T2DM. Recently, some studies found a weak but positive
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association of bisphenol (found in some plastic types) concentration in the urine and
T2DM (18).
Type

Characteristic
Clinical comment

Type 1

Autoimmune,

previously

called Potential association with

juvenile or insulin-dependent diabetes other autoimmune diseases
mellitus
Type 2

Polygenic and affected by environment

Increasing incidence
associated with higher
life span and western
cultural habits

Gestational

Secondary

Rapid clinical

Can continue after

Progress

pregnancy

Side effect of medications

Causative disease or

or pancreas dysfunction (e.g: steroids, medication may also
and alcoholism)

influence ocular and
lacrimal function

Genetic

Genetic defects in insulin secretion or Potential ocular
action

associated
malformations

Table 1: Classification and observations on types of diabetes mellitus (19)

5

According to the International Diabetes Federation (IDF) statistics, it was
estimated that 366 million people were diabetic in 2011; this number increased to
387 million in 2014. DM led to almost 4.6 million deaths in 2011 (20). Estimates by
the IDF indicate that the number of diabetics is expected to rise and reach up 592
million by 2035 (1).

The prevalence of diabetes is increasing in the general

population every year. This increase is attributed mainly to sedentary life style,
increased intake of high calorie diet, central obesity (large abdomen), and a high
body mass index (BMI: weight (kg)/height (m)2). Almost 80% of people with DM
live in low- and middle-income countries (21). The incidence of T2DM varies
noticeably from one geographical region to another, as a result of environmental and
lifestyle risk factors. Though prevalence of T2DM in Africa has been low, studies
have shown a drastic increase in prevalence in both rural and urban areas, and
affecting both gender similarly (20).
In the last few years, there has been a drastic rise in T2DM among all age
groups. The UAE has been a member of the IDF since 2000; it comes under the
Middle East and North Africa (MENA) region. The MENA region has the second
highest prevalence (9.7%) of diabetes in the regions (figure 1). The UAE has the one
of the largest number of diabetics in the world; around 19% of the UAE population is
diabetic (22). There were 803,900 cases of diabetes in UAE in 2014. These numbers
are expected to increase each year (20).
These figures indicate that the region has high risk factors for diabetes, mainly due to
the rising levels of obesity and physical inactivity.
Sedentary lifestyle and increased consumption of unhealthy diet are the main
contributors to the increased levels of obesity in the UAE. High-risk people need to
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be alert about their physical activities and diet. This can decrease the chances of
developing more complications. Better understanding of the early symptoms of
diabetes help people to be prepared to manage the disease and its complications (20).

Figure1 : International Diabetes Federation; world regional diabetes classification.
(21)

1.4 Metabolic changes in Type 1 diabetes
T1DM is considered a more simple type of diabetes when compared to
T2DM. Despite high blood glucose levels, the cells seem to lack glucose as its
uptake is insufficient due to insulin deficiency.

As a result, the liver keeps

synthesizing glucose (gluconeogenesis) and ketone bodies (ketogenesis).

High

glucagon levels have adverse action in DM. The increased glucagon/ insulin ratio
lead to decreased levels of fructose 2,6 bisphosphate that is vital for activating
glycolysis and inhibiting gluconeogenesis.

Failure of glycolysis and excessive
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gluconeogenesis exacerbate hyperglycemia.

Glucose is secreted in the urine

accompanied by water; this explains the thirst and excessive urination in acute
diabetes (23).
Insulin deficiency affects other hormonal secretions such as decreased leptin
from the adipose tissue and increased glucagon secretion.

Recent studies have

shown that leptin deficiency in diabetic rats lead to increased pituitary gland
production of adenocorticotropin hormone (ACTH). This hormone stimulates the
production of corticosterone from the adrenal gland, leading to increased lipolysis
and production of free fatty acids (FFA) and glycerol from triglycerides. The FFA
and glycerol produced reach the liver via the blood and get converted to glucose and
ketone bodies. This leads to hyperglycemia and ketoacidosis (15). Β oxidation
produces acetyl CoA which in this case is unable to enter the TCA cycle due to
insufficient oxaloacetate (from pyruvate as an end-product of glycolysis).

The

energy supply is changed to fat instead of carbohydrates. The high concentration of
ketone bodies affects the kidneys’ ability to maintain the acid-base balance.
Uncontrolled diabetes can lead to coma due to low blood pH levels and
dehydration. Ketosis is not seen in T2DM, as the insulin is sufficiently active to
prevent lipolysis in the liver and adipose tissue (23).
1.5 Metabolic changes in Type 2 diabetes
T2DM is the most common endocrine metabolic disorder and is characterized
by insulin resistance and pancreatic islet β-cell failure. Obesity, inflammation,
oxidative stress, mitochondrial dysfunction have been implicated as etiological and
pathophysiological risk factors for T2DM. Cardiomyopathy and other cardiovascular
complications associated with increased inflammatory and oxidative stress responses
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are the major causes of accelerated atherosclerosis in obesity and diabetes. Insulin
resistance is an early feature in T2DM development (24-27).

Obesity is considered as one of the main reasons for developing insulin
resistance in T2DM. Inappropriate diet-related obesity and visceral adiposity are the
main risk factors for the development of T2DM. Many studies have shown that
nutrient-induced β-cell dysfunction could be related to indirect initiation of low grade
inflammation (28).

Hypertriacylglyceridemia and hypercholesterolemia due to

increased circulating lipoproteins, may lead to high levels of triglycerides in blood
and tissues that exceed the storage capability of adipocytes, leading to fat deposition
in the organs. The liver and muscles are the main sites for fat deposition. Fat
accumulation leads to the development of insulin resistance. The rate of fatty acid βoxidation increases in response to high fat concentration. The mitochondria reach a
limit where they are unable to process the extra fatty acids by β-oxidation.
Consequently, fat is deposited in the cytoplasm and is accompanied by increased
levels of diacylglycerol and ceramide. Diacylglycerol activates protein kinase C
which regulates insulin receptor substrate (IRS) mediated insulin signaling leading to
reduced insulin sensitivity. Ceramide inhibits glucose uptake and glycogen synthesis
(23).
In T2DM, mitochondrial dysfunction in the tissues, particularly in the pancreas,
due to proinflammatory responses and disturbance in redox homeostasis signaling
have also been reported which may lead to increased oxidative stress (26). Studies
have also suggested that prolonged exposure to insulin, as seen in resistant T2DM
suppresses mitochondrial biogenesis and function and this may lead to impairment of
insulin sensitivity (29-30).
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In chronic uncontrolled T2DM, insulin resistance induces stress on the β-cells in
the pancreas to produce more proinsulin.

Proinsulin is stored in the ER, and

excessive amounts can cause ER stress. The ER stress lead to a signal induction that
eventually protects the cell from damage. It removes the extra proteins, and inhibits
general protein synthesis. If this fails to relieve the ER stress, apoptosis is activated
leading to β cell death (23).
1.6 Insulin structure
Insulin was discovered in 1921 by Banting and Best (31). It is a small protein
with a molecular weight of 6000 Daltons. It is made from two chains bound together
by disulfide bonds.

Insulin's amino acids are highly conserved in vertebrates;

structurally same insulin is active in different mammals. Most insulin used to treat
diabetics is extracted from pig’s pancreas (32).
1.6.1 Biosynthesis of insulin
Insulin is synthesized in large quantities in the β-cells of the pancreas. Insulin
mRNA is first translated as preproinsulin which is a single chain insulin precursor,
which is then converted to proinsulin when the peptide group is removed after being
moved to the ER (Figure 2).
Proinsulin is made of three parts: an amino terminal A that consists of 21 amino
acids, a carboxy terminal B chain which consists of 30 amino acids, and a C-peptide
in the middle. In the ER, many specific endopeptidases cut off the C peptide to form
the mature form of insulin leaving the A chain and B chain connected together with a
disulphide bond between A7- B7 and A20- B19. Mature insulin and free C peptide are
packaged in the Golgi and stored in secretory granules in the cytoplasm (33).
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Figure 2: Insulin synthesis (183)
Insulin production is stimulated by high blood glucose level, some neural
stimuli, and high levels of fatty amino acids. Glucose metabolism is needed for
insulin release to be stimulated, this activates a sequence of events including
generation of ATP, closure of K+ channels in the β-cell membrane and increased
Ca2+ entry into the cell. Subsequently, the β-cells excrete insulin by exocytosis and it
diffuses in to the blood (34). C peptides are also secreted, but their functions are not
known. Insulin released into the blood circulation is recognized by insulin receptors
in target cells.

1.7 Insulin receptor and cell signaling
Insulin receptors (IR) are heterotetrameric glycoproteins on the cell surface.
They consist of two α extracellular subunits that attach to insulin, and two β subunits
that have tyrosine kinase specific protein activity, with a disulphide bond to link
them. When an insulin molecule attaches to the receptor extracellularly, the tyrosine
kinase is activated leading to the receptor's autophosphorylation and other
intracellular proteins as well (insulin substrates -1, -2, -3, and -4).

Multiple

downstream signaling pathways are activated after the phosphorylation (Figure 3).
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The insulin receptor has different proximal substrates. These include IRS-1,
IRS-2, IRS-3, IRS-4. IRS-1 and IRS-2 are the most expressed substrates, whereas
IRS-4 is only expressed in the brain, kidney and thymus. IRS-3 is expressed in the
adipose tissue of rodents (35).
The insulin signaling pathway starts when an insulin molecule binds to the
insulin receptor (IR) activating tyrosine kinase activity (Figure 3). The activated IR
phosphorylates and recruits different substrates such as IRS-1 and IRS-2. The
tyrosine phosphorylated IRS then provides binding sites for many signaling
molecules. Among them, PI3K has a vital role in insulin function, mainly by the
activation of the Akt/PKB and the PKCζ cascades. Activated Akt then activates
glycogen synthesis through inhibition of GSK-3; protein synthesis through mTOR
and downstream elements; and cell survival through inhibition of many pro-apoptotic
agents, such as (Bad, FoxO transcription factors, GSK-3, and MST1). Akt
phosphorylates and inhibits FoxO transcription factors that control metabolism and
autophagy. AMPK also directly regulates FoxO3 and activates transcriptional
activity. Insulin signaling plays a vital role in growth and mitogenic effects that are
mediated by the Akt cascade as well as by activation of the Ras/MAPK pathway.
Insulin stimulates glucose uptake in muscles and adipocytes through the
translocation of GLUT4 vesicles to the plasma membrane. Furthermore, insulin
signaling

prevents

gluconeogenesis

in

the

liver,

by

interfering

with

CREB/CBP/mTORC2 binding. Insulin signaling activates fatty acid and cholesterol
synthesis by regulating SREBP transcription factors (36).
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Hyperinsulinemia is a major characteristic of the metabolic syndrome. It is
the over production of insulin from pancreatic β-cells, and is considered a primary
contributor to T2DM development and cardiovascular dysfunction (37).
Understanding the mechanisms of insulin action and resistance is a vital step
in the management of metabolic syndrome as well as development of therapeutic
interventions to prevent or treat T2DM.

Figure 3: Insulin Receptor stimulation. (182)
1.8 Insulin and glucagon hormonal responses in diabetes
Insulin and glucagon are considered the most important two hormones in
diabetes. Insulin is released in case of elevated blood glucose levels to stimulate
glucose uptake by the liver and muscle to lower circulating glucose level. Glucagon
is secreted in case of decreased blood glucose levels, it increases glucose production
from the liver to maintain normal blood glucose levels. Most studies focus on
insulin, whereas glucagon has been interpreted as a consequence, rather than a cause
of diabetes. But several studies have concluded that there is an association between
elevated glucagon secretion and T2DM.
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Weiping Han and co-workers at the A*STAR Singapore Bioimaging
Consortium concluded from a study done in 2010 that dysregulated glucagon
secretion, or lack of glucagon secretion inhibition with high blood glucose levels, can
be a reason to develop T2DM. The study design included a high-fat diet given to
normal mice and to genetically modified ‘knockout’ mice with impaired glucose
tolerance, low insulin secretion and very less glucagon secretion. High-fat diet is
known to reduce insulin sensitivity in mice. It was predicted that the knockout mice
(known to have impaired insulin secretion) will develop T2DM sooner than the
control mice. Surprisingly, the control mice developed high glucose levels, whereas
the knockout mice did not. This finding is evidence that reduced insulin secretion
and sensitivity may not be the only factors to the development of T2DM, but also
dysregulated glucagon secretion. That is why diabetes should be considered as a bihormonal disease and more studies should focus on glucagon regulation (38-39).
1.9 Insulin resistance in diabetes
One of the main characteristics of T2DM is insulin resistance, when cells are
unresponsive to insulin signaling.

In the late stages of insulin resistance, the

pancreatic β cells fail to produce sufficient amounts of insulin. Which eventually
affects insulin signaling.

Skeletal muscles play an important role in insulin

resistance, being the major organ for glucose storage obtained from food (40).
Alterations in lipid metabolism and mitochondrial dysfunction in skeletal muscle
have been connected to the etiology of T2DM but the underlying relationships with
insulin resistance development remain to be clarified (41-42). Increased levels of
lipid oxidation are seen in the early stages of insulin resistance; however increased
plasma levels of non-esterified fatty acids (NEFA) inhibit glucose uptake and
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glycogen synthesis in skeletal muscles (43). Additionally, it has been found that
there is an increase in intramyocellular lipids (IMCL) (44).
Insulin resistance, also known as insulin resistance syndrome is a major
causative factor of metabolic syndrome. There has been an alarming increase in
metabolic syndrome. The main reasons for this syndrome are obesity,
hyperglycemia, hyperlipidemia, and hypertension.

Various animal studies have

demonstrated the role of insulin and its signaling cascade in controlling cell growth,
metabolism and survival through the activation of mitogen activated protein kinase
(MAPKs) and phosphotidylinositide 3 kinase (PI3K). PI3K activation is associated
with insulin receptor substrate 1, 2 (IRS1, 2) and eventually Akt and FOXO 1
phoshporylation. This cascade plays a vital role in nutrient homeostasis control and
organ survival. Hyperinsulinemia, metabolic inflammation, and over nutrition lead
to inactivation of Akt and activation of FOXO 1, by suppressing IRS1, 2 in different
organs leading to metabolic syndrome. A good therapeutic intervention for diabetes
and its complications could be through targeting IRS, Akt, FOXO 1 signaling
cascade (4).
Patients with T1DM suffer from insulin deficiency due to failure of
pancreatic β-cells to produce insulin. The therapeutic intervention is insulin
supplement to control hyperglycemia. The scenario is different in T2DM, where
pancreatic β-cells are producing sufficient insulin, which is not utilized properly.
T2DM is non-insulin dependent, although insulin therapy can help reduce the
hyperglycemia, but weight gain and cardiovascular risks are exacerbated.
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Figure 4: Hypothesized time course of T2DM progression.
Insulin sensitivity (black line), acute insulin response (AIR, blue line), and blood
glucose (red line). Impaired insulin sensitivity arises before evident changes in
glucose; the insensitivity is compensated by an increased insulin secretion (AIR)
during normoglycemia (blue shading). However, overtime AIR declines leading to
impaired fasting glucose (gray shading) and development of T2DM (45).

1.10 Chronic metabolic complications of diabetes
As mentioned above, diabetic complications which arise due to insulin
insufficiency (type 1) or insulin resistance (type 2) may develop into metabolic stress
associated with energy metabolism, mitochondrial dysfunction and oxidative stress.
These alterations may further complicate the pathophysiology of disease due to
progressive accumulation of advanced glycation end products (AGE) leading to
neuropathic, nephropathic and retinopathic symptoms complications. Some of these
metabolic etiological and pathophysiological factors are discussed below.
1.10. 1 Oxidative stress in diabetes
Many experiments and clinical trials have shown that oxidative stress has a
major role in the development of diabetes mellitus.

Excessive reactive oxygen
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species (ROS) are produced in diabetes. There are different cellular sources of ROS
generation: peroxisomes, plasma membrane proteins, such as NADPH oxidase
(NOX), cytosolic enzymatic reactions, and mitochondria. Mitochondria produce
around 90% of total cellular ROS (46). Around 1% to 5% of the mitochondrial
oxygen consumption is converted into superoxide anions and other ROS (47).
Mitochondrial dysfunction leads to increased ROS production, increasing the
potential for chromosomal abnormalities (48). Increased ROS production has been
implicated in abnormal glucose oxidation, non-enzymatic glycation of proteins, and
oxidative degradation of glycated proteins. High levels of ROS production and low
levels of cellular anti-oxidant defense may damage cellular organelles and enzymes;
it also increases lipid peroxidation leading to insulin resistance. The most important
and first ROS generated by either mitochondria or by NOX is superoxide (O2-.).
Superoxide anion radicals get dismutated by superoxide dismutase (SOD) to
hydrogen peroxide (H2O2), which is eventually degraded under normal conditions by
catalase or glutathione peroxidase enzyme systems.

Excess H2O2 which is not

metabolized by these antioxidant enzymes may also be non-enzymatically
metabolized by Fe2+ or other divalent ions to produce hydroxyl radicals. Superoxide
anions react with nitric oxide producing reactive peroxy-nitrite radicals (ONOO-).
Hyperglycemia, as seen in diabetes, increases lipid peroxidation of low
density lipoprotein (LDL) using a superoxide dependent pathway producing free
radicals. Hyperglycemia increases the levels of glucose that interact with proteins,
producing Amadori products followed by advanced glycation end products (AGEs).
The AGEs receptors (RAGEs) inactivate some enzymes by altering their structures
leading to malfunctioning. RAGEs also promote free radical formation, and inhibit
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the anti-proliferative effects of nitric oxide. As AGEs increase oxidative stress, they
promote the up-regulation of various NF-kβ target genes. NF-kβ increases nitric
oxide production, which is an islet β cell damage mediator (49-50).
Glucose plays a major role in activating the sorbitol (polyol) pathway that
leads to diabetes complications, such as eye lens cataract and neuropathy. Increased
sorbitol dehydrogenase activity is closely related to altered NAD+ levels that lead to
protein modification by non-enzymatic glycosylation of lens protein. However, the
mechanisms are still not fully understood (51-52).
1.10.2 Redox homeostasis in diabetes
Coupled oxidation reduction (redox) reactions, are vital to survival. ROS are
by-products of metabolism. Natural antioxidants include vitamins (A, C, and E),
glutathione, and enzymatic antioxidants such as superoxide dismutase, catalase,
glutathione peroxidase and glutathione reductase (53).

They work in harmony

remove ROS and control its adverse effects in the body.
evidence for increased levels of oxidative stress in T2DM.

There are countable
The expression of

antioxidants (SOD1, SOD 2, and catalases) in pancreatic β-cells is low compared to
other tissues. Chronic diabetes decreases the γ-glutamylcysteine ligase, the rate
limiting enzyme for glutathione synthesis.

T2DM is associated with elevated

markers of chronic oxidative stress, as β cells maintain a low level of antioxidant
gene expression with a high level of glucose to inhibit the rate limiting enzyme for
glutathione (54). Prolonged hyperglycemia and hyperlipidemia are considered the
main causes of increased oxidative stress, mitochondrial dysfunction, and fibrosis
with diabetes complications.
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1.10.3 Mitochondrial dysfunction
Cellular energy is produced by the mitochondria through inner membrane
bound respiratory chain electron transport enzymes and oxidative phosphorylation
(OXPHOS) of ADP. It also produces (ROS).

The mitochondrion is the main

organelle controlling programmed cell death which is caused by energetic deficiency
and ROS damage associated oxidative stress. Most of the cellular ROS (O2-, H2O2
and OH.) are toxic byproducts of mitochondrial OXPHOS. Increased ROS
production due to abnormal oxygen metabolism in diabetes may result in reduced
bioenergetics and mitochondrial dysfunction which ultimately may lead to insulin
resistance and other complications of cell survival and death (apoptosis/mitophagy).
The mitochondrial inner membrane respiratory complex enzymes include five
multipolypeptide enzyme complexes. Complexes I, II, III and IV make up the
electron transport chain (ETC) and Complex V is adenosine triphoshpate (ATP)
synthase.
Metabolism of carbohydrates and fats generate NADH and FADH2 which
donate electrons to the ETC. Complex I oxidizes the NADH+ (NADH: ubiquinone
oxidoreductase, or NADH dehydrogenase). Electrons are transported to ubiquinine
(CoQ10) that gets reduced to ubisemiquinone (CoQ10H).

Electrons are then

transported to Complex II from succinate (succinate oxidoreductase, succinate
dehydrogenase (SDH)) that reduces CoQ10 to CoQ10H. The electrons are then ferried
to Complex III (ubiquinol: ferrocytochrome c oxidoreductase) to move them to
cytochrome c. Electrons are then passed on to complex IV (ferrocytochrome c:
oxygen oxidoreductase), resulting in the formation of H2O (Figure 5). The energy
produced is used for proton pumping from the mitochondrial matrix through the
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mitochondrial inner membrane, to the intermembrane space via complexes I, III, and
IV.
Abnormal mitochondrial respiratory complexes structure and /or function
may lead to the leakage of electrons from ETC. Single electron reduction of oxygen
in the mitochondria may produce ROS. Increased ROS production may further
increase oxidative modification and inhibition of respiratory complexes which might
trigger the production of more ROS, i.e. ROS-induced ROS production. Some of the
consequences of dysfunctional respiration have been studied. A point mutation in
the mitochondrial DNA (mtDNA) gene MTATP6 reduces mitochondrial respiratory
activity and helps cancer promotion by inhibiting apoptosis (55) (56). Growing
evidence suggests that mitochondrial dysfunction due to oxidative damage is a major
cause of aging, degenerative diseases like cancer, and metabolic syndrome, such as
obesity and T2DM (42, 56).
Insulin resistance in skeletal muscle plays a vital role in the pathogenesis of
metabolic syndrome and T2DM. Recent studies reported that insulin resistance is
associated with impaired skeletal muscle oxidation capacity and reduced
mitochondrial number and function (57). Protecting the mitochondria from oxidative
damage in order to improve mitochondrial function in skeletal muscle is a strategy to
prevent and treat diseases associated with mitochondrial dysfunction (58).
Rosiglitazone improves the suppression of adipose mitochondrial biogenesis in db/db
and high fat diet-fed mice (59). Pioglitazone works by reducing hyperglycemia,
hyperlipidemia, and hyperinsulinemia in male fatty rats (60), it also improves
mitochondrial function and stimulates mitochondrial biogenesis in human
adipocyte/tissue in vitro (61) or human neuron-like cells (62). Metformin has a role
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in delaying the expression of diabetes and vascular dysfunction; it also decreases
mitochondrial oxidative stress in Goto-Kakizaki (GK) rats (63). However, trials
have shown that any pharmacological therapy for T2DM, such as thiazolidinedione,
insulin, metformin, and other oral hypoglycemic agents or combination therapy with
or without insulin is associated with an increased risk of heart failure and body
weight gain. Therefore, effective treatments without obvious side effects are needed
for preventing and treating diabetes and other metabolic syndromes (64).

Figure 5: Mitochondrial respiratory chain (65)

1.11 Mitochondrial structural and functional integrity in diabetes
T2DM is 2-3 times more probable in individuals with diabetic mothers, and
risk doubles if the father is diabetic. DM is significantly linked with mitochondrial
system, mainly mtDNA mutations. Researchers found a 10.4 kb deletion in mtDNA
light strand origin of replication (OL) in maternally inherited IDDM. They also found
the A3243G mutation that is associated with mitochondrial encephalopathy in
T2DM. A3243G is transmitted through a carrier mother to all her children and by 80
years of age, almost all of them will develop DM (66).
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Changes in mtDNA in T2DM are both qualitative and quantitative, a 35%
decrease of mtDNA in peripheral leukocytes in T2DM patients compared to the
control group. Reduction was also found in presymptomatic patients who developed
the disease two years later. A 50% decrease in skeletal muscle mtDNA was found in
T2DM patients but four genes encoded by mtDNA (COI, COIII, ND4 and 12s
rRNA) had 1.5-2.0 fold increased expression. Similar decreases have been found in
GK T2DM rats. Such decrease leads to impaired insulin secretion (66-67).
Glucose stimulated insulin secretion (GSIS) is strongly linked to
mitochondrial functional integrity. Insulin release is inhibited by (ETC) function
inhibitors like: rotenone, antimycin A, sodium azide, and cyanide. In pancreatic β
cell islets, the high capacity, low affinity receptors GluT1, and GluT2 helps the
glucose equilibrium across the plasma membrane (67).
Sufficient extra and intracellular glucose equilibrium is maintained by
GLUT2 high capacity that is 100 times double the maximal rate of glycolysis.
Cytosolic kinase (an enzyme that controls the rate of flux through glycolysis and
pyruvate generation) phosphorylates glucose to glucose 6-phosphate.

Pyruvate

generated from glycolysis enters the mitochondrial TCA cycle. A high level of
glucose derived carbon enters the β cells and gets converted to mitochondrial CO2.
Mitochondrial pyruvate is metabolized by pyruvate dehydrogenase, generating
acetyl-CoA or pyruvate carboxylase to form oxaloacetate to ensure anaplerosis to the
TCA cycle. Anaplerosis can be crucial in pyruvate/malate shuttle activation causing
an increase in cytosolic NADPH. TCA cycle generates reducing equivalents in the
form of NADH and FADH2 that are transformed to mitochondrial ETC with
Adenine Triphosphate (ATP) production. Systolic ATP/ADP ratio increase as the
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ATP enters through adenine nucleotide translocase (ANT), this results in
depolarization of the plasma membrane as the ATP sensitive K+ channels close. βcell UCP-2 up regulation leads to increased ROS production, decreased ATP, ATPK+ sensitive channels closure and eventually impaired insulin secretion. In mice
models the knockout of UCP-2 activity leads to improved β cell ATP production and
during glucose stimulation, insulin gets secreted. Plasma depolarization leads to
Ca+2 sensitive channels opening and a sharp increase in systolic Ca2+, the main event
for insulin secretion by exocytosis of secretory granules (56).
Animal models demonstrated evidence to the intact mitochondrial ETC
function for insulin release. Mitochondrial DNA is needed for glucose-induced
stimulus secretion coupling in pancreatic β cells (MIN6) of mice. Insulin is affected
by the glucose stimulated Ca2+ inhibition which is a result of mitochondrial MIN6
depletion (56).
1.12 Advanced glycation end-product (AGE) and diabetes
Hyperglycemia, whether extracellular or intracellular have damaging effects
on different organs. Extracellular hyperglycemia leads to the formation of AGEs
while intracellular hyperglycemia increases mitochondrial activity, protein kinase C
(PKC), and NADPH oxidase, promoting oxidative stress complications and
inhibition of insulin signaling pathway.
Many researchers still consider hyperglycemia as the main factor for
developing diabetic complications. Hyperglycemia contributes to the formation of
AGEs.

AGEs are formed early in embryonic life, but at a slower rate when

compared to diabetics. This increase is due to high levels of glucose. AGEs are a
heterogenous group of molecules, made from the non-enzymatic reaction between
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reducing sugars and free amino groups originating from proteins, lipids, and nucleic
acids.

The first product of the previous interaction is the Schiff base, which

rearranges itself to make the amadori products (e.g. haemoglobin A1c ). AGEs
covalently bind to proteins, leading to altered protein structures and functions. AGEs
also interact with their cell surface binding receptors (RAGEs).

AGEs are

endocytosed and either degraded or lead to the activation of pro-oxidant and
inflammatory responses (68).
AGEs play a role in developing micro and macro angiopathies. High levels
of AGEs are present in diabetics’ retinal vessels. The higher the level of AGEs, the
more severe the retinopathy. Aminoguanidine is used to inhibit AGEs formation in
diabetic patients, and help to reduce its complications.
AGEs are found in large quantities in the peripheral nerves of diabetics. The
use of AGE inhibitors showed improved nerve conduction velocity and neuronal
blood flow.
AGEs are also found in high concentrations in diabetics’ nephrons, which
lead to glomerulosclerosis and interstitial fibrosis due to thickened glomerular
basement membrane and mesangial expansion.
Animal and human studies have shown that AGEs contribute in the
development of cardiovascular diseases. They alter normal blood vessel and smooth
muscle structure making them atherogenic. AGEs also change the LDL cholesterol
structure and make it prone to oxidation, leading to its deposition in the blood vessels
wall (68).
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1.13 Glucokinase mutations in diabetes
Glucokinase, a member of the hexokinase enzymes, is located on
chromosome 7p 15.3- 15. It consists of 12 exons that span 45,168 bp and encode for
a 465-amino acid protein, its molecular weight is 52,191 Da. It is expressed in the
pancreas, liver, brain, and endocrine cells.

Tissue specific promoters helps in

differential regulation and transcription of different transcripts resulting in three exon
1 (a,b,c) that differ in size. The upstream promoter is active in the pancreas and
brain, whereas the downstream promoter is active only in the liver. It works as a
monomer; it helps to phosphorylate glucose on carbon 6 with Mg-ATP to form
glucose-6-phosphate (G6P). It is a glucose sensor in pancreatic β-cells. Glucokinase
is a key regulatory enzyme for insulin secretion. There are many mutations in
glucokinase gene (GCK) (620 mutations found) and most are in the protein area
called allosteric activator site.

Glucokinase mutations cause reduced insulin

secretion, and lower glucose uptake by the liver leading to type 2 diabetes mellitus
(69-70).

1.14 Diseases associated with diabetes complications
Long term diabetes increases the chances of developing many complications
in different organs. These complications contribute to increased diabetes morbidity
and mortality rate. The development of different complications is related to diabetes
duration and glycemic control. The organs that develop diabetic complications show
insulin independent glucose uptake. Aldose reductase induces nicotinamide adenine
dinucleotide phosphate (reduced form) (NADPH) to activate the pentose phosphate
pathway, which leads to a protein kinase C–induced increase in glomerular
prostaglandin production and loss of mesangial cell contractility, which can be a
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cause of hyper-filtration and glomerular dysfunction in diabetes (71-72). Impaired
insulin and growth factor signaling, hyperlipidemia and hypertension are major
factors for the development of diabetic complications. The most common diabetic
complications are macrovascular disease, nephropathy, retinopathy and neuropathy
diseases. (71) (Figure 6).

Figure 6: Major complications of diabetes mellitus (73)

1.14.1 Diabetic Retinopathy
Diabetic retinopathy (DR) is a microvascular complication which might harm
the peripheral retina, the macula, or both. It is considered a major cause of vision
disability and blindness in diabetics.

The severity of DR ranges from non-

proliferative and pre-proliferative to the more serious proliferative DR, where
abnormal new vessels are formed. Neglecting vision problems in diabetics can
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eventually lead to partial or complete blindness through hemorrhage or retinal
detachment (74). Prolonged diabetics are more susceptible to DR. A recent study in
patients with both T1DM and T2DM, showed that after 30 years of diabetes, most of
the patients developed some degree of DR, and more than half developed
proliferative DR. T1DM and people taking insulin had the highest prevalence of DR
(75).

Another study concluded that retinopathy can occur as a late stage

complication in T1DM, while in T2DM 20% of patients are diagnosed with
retinopathy at the time of diabetes diagnosis (76).
Loss of pericytes is an early marker for DR.

Pericytes are elongated

contractile cells that surround endothelial cells of small vessels, they play a role in
maintenance of capillary tone (ie, dilatation and constriction), and protection against
ROS damage. Loss of pericytes in DR would affect normal capillary constriction as
well as new capillary generation (77).
1.14.2 Diabetic neuropathy
Diabetic neuropathy is due to damage in peripheral nerves. There are two
types of peripheral neuropathies: focal mononeuropathies and sensorimotor
polyneuropathies. One of the most common examples is feet nerve damage, due to
poor blood flow that increases the chances of various foot complications. This can
cause tingling, numbness, burning or pain which begins at the tips of the toes or
fingers and slowly spreads upward. Neglecting the signs and untreated cuts and
blisters can lead to the development of serious infections; they heal slowly and may
ultimately require toe, foot or leg amputation (78).
Researchers found that diabetic mice fed high cholesterol diet, developed
severe hypertriglyceridemia and advanced atherosclerosis. The previous finding
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suggests that lesion progression is exacerbated in obese diabetics who mostly have
T1DM (78).
1.14.3 Diabetic nephropathy
Diabetic nephropathy (DN) is caused by damage to small blood vessels in the
kidneys leading to decreased kidney efficiency or failure. Diabetics are more prone
to develop kidney disease. Retaining near normal levels of blood glucose and blood
pressure can significantly reduce the risk of kidney disease (79).
The first sign of DN is usually microalbuminuria, which progresses to overt
and more severe renal dysfunction and ultimately to renal failure and is the leading
cause of end-stage renal disease (ESRD) (80).
Around 25% of people with T2DM have microalbuminuria or a more
advanced stage of DN. Patients with DN also show thickening of glomerular
basement membranes and glomerular hyperfiltration, which leads to mesangial
(centre of the renal glomerulus) extracellular matrix extension and promotes
increased urinary albumin excretion and development of glomerular and tubular
sclerosis and renal failure. The risk factors for DN include hyperglycemia, duration
of diabetes, age of onset, tobacco use, dyslipidemia, hypertension, and obesity (75).
1.14.4 Macrovascular complications
DM is considered as a major risk factor for developing cardiovascular events.
The Framingham Heart Study described diabetes as one of the causative factors
associated with probable ratios for coronary heart disease of 1.5 and 1.8 for men and
women, and risks for stroke of 1.4 and 1.7 for men and women, respectively (81).
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Diabetics have a 2- to 4-fold increased possibility of developing cardiovascular
events compared to non-diabetics (82).
Heart disease in DM develops as a result of negative modulation at different
levels leading to vascular (angiopathy), myocardial (diabetic cardiomyopathy), and
intracardial nervous (autonomic neuropathy) dysfunction. Coronary artery disease
(CAD), which eventually leads to occlusion of arteries that supply the heart, has been
reported to be directly responsible for much of the condition of CVD in patients with
DM. Atherosclerotic CAD is more frequent and more severe in diabetics when
compared to non-diabetics (83).
Both types of diabetes mellitus (type 1 and 2) have irreversible effects on
small and large blood vessels. Oxidative stress and inflammation remarkably alter
gene expression in the vasculature.

Imbalance between pro-inflammatory and

thrombogenic systems in diabetics are key contributors in developing the pathology
of the disease.

Eventually, the above mentioned few points lead to failure of

vascular repair. Macrovascular complications leading to heart attacks and strokes are
considered the main cause of death among diabetics (84).
CVD is very common in diabetes and particularly in T2DM, particularly in
uncontrolled diabetes. These patients are 2-6 times more prone to develop CVD
compared to people with other types of diabetes. CVD is responsible for half of the
diabetes deaths.

It includes angina, myocardial infarction and congestive heart

failure (85).
1.15 Pharmacology and therapeutics in diabetes
DM progresses to tissue or vascular damage, leading to severe complications
such as retinopathy, neuropathy, nephropathy, cardiovascular complications and
ulceration (86). Thus, DM is involved in a wide range of heterogeneous diseases.
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Medications are basically used to save lives and relieve symptoms. Secondary aims
of treatment are to prevent long-term diabetic complications and, by eliminating
various risk factors, to increase durability. T1DM treatment is mainly by insulin
replacement, while diet control and active lifestyle are considered the basis for
treatment and management. Insulin supplements are also vital in T2DM when blood
glucose levels cannot be controlled by diet, weight loss, exercise and oral
medications. Oral hypoglycemic agents like sulphonylureas, biguanides, alpha
glucosidase inhibitors, meglitinide analogues, and thiazolidenediones help in
controlling T2DM.

The main role of hypoglycemic drugs is to control the

underlying metabolic disorder, such as insulin resistance and inadequate insulin
secretion. They are prescribed in combination with a low calorie diet and lifestyle
changes. Diet and lifestyle help to reduce weight, improve glycemic control and
reduce the risk of developing cardiovascular complications, which cause 70% to 80%
of deaths among diabetics (87).
Oral administration of stevioside improves insulin sensitivity, and seems
suitable as an adjuvant for diabetic patients and/or those that ingest large amounts of
fructose (88).
Pharmacological treatments that increase brain and hypothalamic insulin
sensitivity may provide new strategies for the prevention of dementia disorders,
obesity, and T2DM (89).
The increase in the intracellular deposition of triglycerides (TG) in muscles,
liver and pancreas in subjects prone to diabetes is well documented and demonstrated
to attenuate glucose metabolism by interfering with insulin signaling and insulin
secretion. The obesity often associated with T2DM is mainly central, resulting in the
overload of abdominal adipocytes with TG and reducing fat depot capacity to protect
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other tissues from utilizing a large proportion of dietary fat. To reduce the excessive
fat outflow from the abdominal depots and prevent the ectopic fat deposition it is
important to decrease the volume of central fat stores or increase the peripheral fat
stores. This can be achieved by gastrointestinal bypass or gastroplasty, which
decreases dietary fat absorption, or by direct means that include surgical removal of
mesenteric fat. Indirect treatment consists of drastic lifestyle change comprising
both diet and exercise and pharmacotherapy that reduces mesenteric fat mass and
activity. The first step should be an attempt to effectively induce a lifestyle change.
Next is pharmacotherapy including acarbose, metformin, PPAR gamma, or PPAR
gamma alpha agonists, statins and orlistat. (90)
There are various reports suggesting the use of antioxidants in the treatment
of diabetes. Some reports provide experimental and clinical evidence supporting
antioxidant supplementation as a cardioprotective intervention in the setting of DM
(91).

Other conflicting reports conclude there is no established benefit for

antioxidant use in the management of diabetic complications (92).
Different side effects have been associated with different hypoglycemic
drugs. Weight gain and hypoglycaemia with sulfonylureas, gastrointestinal (GI)
disturbances with metformin, weight gain, GI disturbances and liver injury with
thiazolidinediones, GI malfunctions, weight gain and hypersensitivity reactions with
meglitinides and flatulence, diarrhea and abdominal swelling with alpha-glucosidase
inhibitors (87).
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1.16 Therapeutic use of Non Steroidal anti inflammatory drugs (NSAIDs) and
aspirin in diabetes

1.16.1 Type 2 diabetes as inflammatory disease
Insulin resistance is the primary cause of T2DM. Increased inflammatory
response is a hall mark of obesity, diabetes and insulin resistance. Use of antiinflammatory drugs may be an approach to increase insulin sensitivity and energy
metabolism. The immune system components are different in patients with T2DM
when compared to normal individuals. Changes are mainly found in adipose tissue,
liver, pancreatic islets, and circulating leukocytes. Factors determining T2DM are
divided into intrinsic and extrinsic factors. Intrinsic factors include mitochondrial
dysfunction, oxidative stress, and lipid deposition.

Extrinsic factors validity,

cytokines, adipokines, serum fatty acids, and hypoxia, interfere with insulin
signaling. Surprisingly, these pathways join the common inflammation pathway. It
is also found that diabetics show changes in some leukocytes activation, higher rates
of apoptosis and fibrosis. Extrinsic factors affect the nuclear factor – κB (NF- κB),
kinase β (Ikkβ), and Jun kinase (JNK) inhibitor. As a result, insulin action gets
inhibited by serine phosphorylation of insulin receptor substrates (IRS1, and IRS2).
Similarly, multiple cytokine signaling suppressors are activated by cytokine proteins
(SOCS) and adipokines, which lead to improper tyrosine kinase phosphorylation of
IRS1, and IRS2, which finally degrade. Consequently, intracellular insulin signal
transduction is inhibited. Pro-inflammatory cytokines (IL-1β, IL-6, IL-8, and IL-12)
and chemokines are also found in insulin resistant T2DM (93). The above variations
support the idea that inflammation plays a role in the development of T2DM. Trials

32

using salicylate with diabetics showed lower blood glucose levels and reduced
disease associated complications (94).
1.16.2 Utility of aspirin therapy in patients with type 2 diabetes
T2DM is strongly linked with cardiometabolic syndrome (CMS), as increased
platelets aggregation and hypercoagulability are the main causes of CMS and to
some extent causes T2DM. Platelets play an important role in atherosclerosis as they
release a number of inflammatory mediators.

Patients with increased levels of

fasting blood glucose show high platelet dependent thrombosis. T2DM patients also
show increased sensitivity of platelet purinergic receptors to ADP, resulting in higher
levels of circulating platelet microaggregates that speed thrombus formation.
For many years aspirin (from NSAID family: non-steroidal anti-inflammatory
drugs) was known by its vasodilator, anti-inflammatory, and anti-thrombotic
functions, it interrupts the synthesis of prostaglandins.

The synthesis happens

through arachidonic acid oxidation that is derived from membrane phospholipids.
After the oxidation, arachidonic acid is transformed by prostaglandin H synthase that
is often called cyclooxygenase (COX). COX helps in the formation of thromboxanes
and prostacyclin, they work as vascular mediators, have a vasodynamic function, and
platelet activity. COX is found in two isoforms (COX1, and COX2). COX 2 is
induced by cytokines and associated with inflammation. Aspirin inhibits both COX
by irreversible serine 530 acetylation, which slows down arachidonic acid entrance
to the active site. Aspirin and sodium salicylate are both known inhibitors of NF-κB
and this may be the mechanism by which they exert their anti-inflammatory effects.
A high dose of aspirin is found to reduce glucosuria in diabetes. High levels of free
fatty acids lead to serine kinase cascade activation, which lead to higher levels of
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TNFα which has a negative effect on insulin signaling. It is also found that TNFα
activates serine phosphorylation of IRS 1 that prevents downstream metabolic
signaling. One study found that aspirin can inhibit 4 out of 6 serine kinase involved
in IRS1 phosphorylation, leading to improved insulin sensitivity by allowing
maximum tyrosine phosphorylation and signaling by P13 kinase and protein kinase B
pathway (95).
Different studies have shown that aspirin therapy is a secondary prevention
approach for cardiovascular events; clinical guidelines recommend using low-dose
aspirin (75-162 mg/day) for the primary prevention and secondary prevention of
CVD in individuals with risk factors. Diabetics are considered as a high risk group,
so they are good candidates for aspirin except for patients with contraindications (96)
(97). The American Diabetes Association (ADA) recommends the use of aspirin as a
primary prevention approach in patients with diabetes who are at increased
cardiovascular risk, including patients with a family history of CVD, hypertension,
smoking, dyslipidemia, or albuminuria and those who are above 45 years of age (98).
1.16.3 Aspirin side effects and aspirin resistance
Nevertheless, due to the action of aspirin on cyclooxygenase (COX), it is
associated with upper GI complications including ulcers and bleeding. The severity
of the side effects is less with low-dose aspirin compared with non-selective,
NSAIDs.

Co-administration of a gastro-protective agent like the proton pump

inhibitors (PPIs) is useful for decreasing the chance of developing upper GI
associated with use of low-dose aspirin. Treating existing H. pylori also helps to
reduce the risk of these side effects, especially in those at high risk (96).
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Aspirin resistance is the failure of aspirin to decrease platelet production of
thromboxane A2.

High degrees of aspirin resistance can be associated with

increasing risk of cardiovascular events. Laboratory tests of platelet thromboxane
A2 production or platelet function that is dependent on platelet thromboxane
production can be used as a measure of aspirin resistance. Possible causes of aspirin
resistance can be insufficient dose, drug interactions, genetic polymorphisms of
COX-1 and other genes needed for thromboxane biosynthesis, upregulation of nonplatelet sources of thromboxane biosynthesis, and increased platelet turnover.
Tackling the reason of aspirin resistance can help in overcoming the problem.
Recent research is focused on defining aspirin resistance, developing dependable
tests for it, and measuring the risk of associated cardiovascular events (99).
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1.17 Aim of the present work
Metabolic complications and atherosclerotic vascular disease is a major cause
of premature morbidity and mortality in obesity and chronic T2DM. Increased
oxidative stress, inflammatory responses and mitochondrial dysfunction have also
been implicated in diabesity. Aspirin and other NSAIDs have been used in many
clinical and experimental trials for the prevention of diabetes, cancer, obesity and
atherosclerotic cardiovascular complications. We therefore, plan to investigate the
effects of aspirin on molecular and metabolic targets altered in diabetes using
expiremental model of T2DM. The GK rat is a spontaneous non-obese animal
experimental model of T2DM. This strain was developed by selective breeding of
glucose intolerant Wistar rats over many generations. The GK rats exhibit decreased
β-cell numbers and function which is accompanied by mild hyperglycemia, impaired
glucose-induced insulin secretion, marked glucose intolerance, peripheral insulin
resistance and chronic inflammation (100-102). Despite the mild hyperglycemia
several manifestations of diabetes complications have been demonstrated in this
model (103-105).
Growing evidence has linked T2DM with low-grade systemic inflammation.
Thus, the GK rat represents a good animal model for studying human T2DMM
pathophysiology and the effects of therapeutic options such as the use of aspirin or
other NSAIDs. It is possible that existing low-grade systemic inflammation can be
suppressed by experimental strategies aimed at blocking the production or action of
proinflammatory signaling pathways, thereby treating T2DM.
Since the objective of the present study was to elucidate the mechanism of
aspirin action in altering metabolic and molecular targets affected in diabetes, we
intended to avoid gastric toxicity caused by oral administration of aspirin, and
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therefore we have selected to administer a low dose aspirin (100 mg/Kg body
weight) intraperitoneally for 5-weeks in young GK T2DM rats.
1.18 Hypothesis
Since inflammation, oxidative stress and mitochondrial dysfunction appears to
be hallmarks of diabetes in general and T2DM in particular, we plan to elucidate the
molecular and biochemical mechanisms of action of aspirin on the pathophysiology
and metabolic complications of T2DM using insulin resistant hyperglycemic GK
rats. Aspirin and other NSAIDs have been used in clinical and experimental trials
for the prevention of diabetes, obesity and other complications. Our specific aims
are to find wither ASA:
1. Improves pancreatic islet β-cell integrity and function.
2. Improves β-cell insulin secretory ability and regulate glucagon synthesis.
3. Improves insulin signaling.
4. Improves glucose uptake and energy metabolism in target tissues.
5. Improves mitochondrial function, oxidative stress and improve antioxidant
redox homeostasis.
6. Alters drug metabolism and detoxification in the tissues in diabetic rats.
ASA might be involved in altering the molecular and metabolic targets affected
in T2DM.
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Chapter 2: Methods

2.1 Chemicals
Aspirin, bovine serum albumin (BSA), picric acid, paraformaldehyde,
trisodium citrate, potassium phosphate,cytochrome c, reduced glutathione (GSH),
oxidized glutathione

(GSSG), 5,5’-dithio-bis(2-nitrobenzoic acid), 1-chloro 2,4-

dinitrobenzene (CDNB), cumene hydroperoxide, dimethylnitrosamine (DMNA),
erythromycin, glutathione reductase, NADH, NADPH, coenzyme Q2, antimycin A,
dodecyl maltoside, sodium succinate, lucigenin and ATP Bioluminescent cell assay
and Hexokinase colorimetric assay kits were purchased from Sigma-Aldrich Fine
Chemicals (St.Louis, MO, USA). 2’, 7’-Dichlorofluorescein diacetate (DCFDA) was
procured from Molecular Probes (Eugene, OR, USA). Polyclonal antibodies against
insulin and glucagon were purchased from Dako, Denmark, while those against Akt,
p-Akt, JNK, p-JNK and β-actin were purchased from Santa Cruz Biotechnology Inc.
(Santa Cruz, CA, USA). Antibodies against PPAR-γ was purchased from Abcam
(Cambridge, UK) while that against 4-HNE was from Oxis Int. Inc. (Portland, OR,
USA). FITC and TRITC conjugated secondary antibodies were purchased from
Jackson Immuno-research Laboratories (West Groove, Pa, USA). Kits for insulin
were purchased from EMD Millipore Corporation (Billerica, MA, USA), PGE2 from
Arbor Assays (Michigan, USA), total nitrate/nitrite from R & D Systems, Inc.,
(Minneapolis, MN, USA), SOD and GDH from Abcam (Cambridge, UK), LPO kit
from Oxis Int. Inc. (Portland, OR, USA). Reagents for SDS-PAGE and Western blot
analyses were purchased from Gibco BRL (Grand Island, NY, USA) and Bio Rad
Laboratories (Richmond, CA, USA).
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2.2 Animals
Ten male GK rats (weighing 100-120 g) were procured from Taconic
(Germantown, NY, USA) at five weeks of age. Ten male Wistar rats of similar age
and weight were procured from the Animal House Facility of College of Medicine &
Health Sciences, United Arab Emirates University (U.A.E) and were used as nondiabetic controls to evaluate the progression of diabetes in GK rats. All animals were
maintained under standard laboratory conditions including a 12-hour light/dark cycle
with free access to food, water and libitum. Approval for this project was obtained
from the Animal Ethics Committee, College of Medicine & Health Sciences
(Protocol Ref#A1-13); U.A.E and all the animals were used following the safe
practice for animals in research guidelines as stipulated by NIH, USA. Body weights
and blood glucose levels (One Touch Ultraglucometer, LifeScan Inc, U.S.A) of the
animals were regularly measured.

2.3 Animal treatment, tissue homogenisation and glucose tolerance test
After 4 months, the GK rats (avg. body wt. 319g) showed signs of
hyperglycemia (fasting blood glucose 80-90 mg/dl) while the control Wistar rats
(avg. body wt. 323g) had a fasting blood glucose level of 50-60 mg/dl. The animals
were then divided into four subgroups, each containing 5 animals. Two subgroups of
GK and Wistar control rats were injected intraperitoneally with 100 mg ASA/kg
body weight/ day) for 5 weeks. This experimental dose and time points were selected
based on the published reports in previous studies, using diabetic models including
GK rats (106-112).

39

In order to avoid gastric toxicity caused by oral administration of aspirin, we
administered aspirin intraperitoneally.
Towards the end of the experiment, the animals were subjected to a glucose tolerance
test. Briefly, after an overnight fast, animals were injected with glucose (2g
glucose/kg body weight) intraperitoneally. Blood samples were collected from the
tail vein at time 0 (prior to the glucose load), 60 and 120 minutes after the glucose
challenge and glucose levels were measured.
At the end of 5 weeks, animals were sacrificed by decapitation and blood was
collected from the jugular vein. Pancreas and the heart from the animals were
quickly excised and a portion of these were fixed in Zamboni's solution and
processed for immunofluorescence studies. The rest of the tissues were stored at -80
o

C until further analysis. Portions of the tissues were homogenized (25 % w/v) in H-

medium (70 mM sucrose, 220 mM mannitol, 2.5 mM HEPES, 2 mM EDTA and 0.1
mM phenylmethylsulfonyl fluoride, pH 7.4) and used for isolating mitochondria,
cytosol and microsome by differential centrifugation. Protein concentration in the
serum and sub-cellular fractions was measured using Bio-Rad reagent as described
before (113-115).

2.4 Serum analysis
Blood samples collected from the jugular vein after decapitation were
transferred into a plain tube. Samples were centrifuged at 4000 rpm for 10-15 min
and the serum was used to assay key organ function tests, cholesterol and
lipoproteins, glucose levels and uric acid using the COBAS® INTEGRA 400 plus
auto-analyzer (Roche, Basel, Switzerland). Insulin, PGE2, total NO and SOD assays
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were also performed in the serum samples using appropriate kits as suggested in
vendor’s protocols and as described before (116-117).
2.5 Insulin assay
Serum insulin level was measured using a non-radioactive quantitative insulin
ELISA kit (Cat# EZRMI-13K). Briefly, serum samples were loaded onto microtiter
plates that were pre-coated with monoclonal mouse anti-rat insulin antibodies to
capture the insulin molecules, followed by addition of biotinylated polyclonal
antibodies that bind to the captured insulin. The addition of horseradish peroxidase
then binds to the immobilized biotinylated antibodies. The activity of horseradish
peroxidase in the presence of 3,3´,5,5´ tetramethylbenzidine was measured at 450
nm. The increase in the absorbency was proportional to the amount of captured
insulin in the sample. The concentration of insulin was calculated from the standard
curve.
2.6 Detection of insulin/glucagon by immunoflurescence staining
Immunofluorescence (IF) is a technique that employs fluorescent-labeled
antibodies to detect specific target antigens. It is commonly used in both scientific
research

and

clinical

laboratories.

In

our

research

we

used

indirect

immmunoflurescence which utilizes a two-step technique (118). Using a primary
unlabeled antibody that binds to the protein of interest (insulin, or glucagon),
followed by loading a fluorophore-labeled secondary antibody (directed against the
Fc region of the primary antibody) to detect the first antibody.
Immunoflurescence staining was performed on pancreatic tissue sections, cut
to 5 μm thickness. Sections were dewaxed by immersing in xylene (two changes) 5
minutes each at room temperature, followed by rehydration in descending
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concentrations of ethanol (100 %, 95 %, 70 %, and 50 %) for 3 minutes each,
washing with distilled water, followed by Antigen retrieval using citrate buffer (pH
6). The slides were then incubated for 1 min in the microwave using power 10,
followed by 10 minutes incubation at power 1 and allowed to cool down to room
temperature for 30 minutes. Slides were washed three times in PBS before incubating
with blocking reagent at room temperature for 45 minutes. This was followed by the
application of the first primary anti-insulin antibody (polyclonal guinea pig anti
insulin diluted at 1:2000), which was incubated overnight at 4 °C followed by PBS
wash (three changes, for 5 minutes each). First secondary antibody (anti-guinea pig
FITC diluted 1:100) was added and incubated for one hour at room temperature.
After a PBS wash (three changes, for 5 minutes each), the second primary antibody
was added (pre-diluted polyclonal rabbit anti human glucagon), and incubated
overnight at 4 °C, followed by Phosphate Buffered Saline (PBS) wash (three
changes, for 5 minutes each). The second secondary antibody (Glucagon: anti-rabbit
TRITC diluted 1:100) was added and incubated for one hour at room temperature
followed by PBS wash (three changes, for 5 minutes each). Finally slides were
washed with PBS (three changes, 5 minutes each) before mounting with CTTIFluore mounting media. Slides were examined using a fluorescence microscope.
Sections were studied using AxioCam HRc digital camera with AxioVision 3.0
software (Carl Zeiss, Oberkochen, Germany) fixed with z-plane fluorescence.
Contrast and brightness of sections were adjusted and images were merged using
image J 1.48V
2.7 Prostaglandin E2 assay
Aspirin has been known for years for its vasodilator, anti-inflammatory, and
anti-thrombotic functions.

Its main function is to inhibit the synthesis of
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prostaglandins. PG synthesis happens through arachidonic acid oxidation that is
derived from membrane phospholipids. After oxidation, arachidonic acid becomes
transformed by the action of prostaglandins H synthase which is better known as
cyclooxygenase (COX) (119).
Prostaglandin (PG) E2 is the most produced PG with different actions. PGE2
is usually considered as an immunosuppressant as it inhibits T cell activation in vitro.
However, in vivo its immunosuppressant action has been unclear. Recently, several
researchers have found that PGE2 facilitates expansion of the Th17 subgroup of T
helper cells of both human and mouse through elevation of cAMP via PGE receptors,
EP2 and EP4 (120).
PGE2 was measured in the serum using the DetectX high sensitivity
immunoassay kit (Cat # K018-HX1). Briefly, standards or diluted samples were
added to a microtiter plate coated with an antibody that captures mouse IgG. A PGE2
– peroxidase conjugate was added followed by a monoclonal antibody to PGE2.
Finally the substrate was added to react with the bound PGE2 conjugate and the color
generated was read at 450 nm using a microtiter plate reader. PGE2 concentration
was calculated from the standard curve.
2.8 Measurement of nitric oxide production
Nitric oxide (NO) is synthesized endogenously by an enzyme nitric oxide
synthase (NOS) from the precursor L-arginine (121). NO is a gaseous free radical
with a short half-life of a few seconds or less. Due to its instability, it is difficult to
measure. Therefore, the levels of the more stable NO metabolites, nitrite (NO2-) and
nitrate (NO3-), have been used to indirectly measure NO. Total NO was measured
using the nitric oxide kit (R &D systems, Inc.) (Cat # ab65328). This assay estimates
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nitric oxide concentrations based on the enzymatic conversion of nitrate to nitrite by
nitrate reductase, followed by the colorimetric detection of nitrite as an azo dye
product of the Griess reaction. The Griess reaction is a two-step diazotization
reaction where acidified NO2- produces a nitrosating agent which reacts with
sulfanilic acid producing a diazonium ion. This ion then couples to N-(1- naphthyl)
ethylene diamine forming the chromophoric azo-derivative that absorbs light at 540 –
570 nm. The reaction mixture containing the reaction diluents, serum samples from
treated and untreated groups, NADH, and diluted nitrate reductase was incubated for
30 mins at room temperature. The reaction was started by adding Griess reagents І
and ІІ, and after an additional incubation for 10 minutes at room temperature, the
absorbance was read at 546 nm. NO concentration in the samples was calculated
from the standard curve.
2.9 Measurement of Superoxide dismutase
ROS, like superoxide radicals, are involved in the pathogenesis of many
diseases. Almost 3 to 10 % of the oxygen used by tissues is converted to its reactive
intermediates that affect the functions of cells and tissues. Superoxide dismutase
(SOD) is an important anti-oxidative (122) enzyme that catalyzes the conversion of
single electron reduced species of molecular oxygen to hydrogen peroxide and
oxygen (O2·- + O2·- + 2H+ → O2 + H2O2) (123).
SOD was measured using Abcam’s Superoxide activity assay kit
(Colorimetric) (Cat # ab65354). It is a sensitive kit that uses a substrate, WST1
which produces a water soluble formazan dye on reduction with superoxide anion.
Reduction rate is linearly related to the xanthine oxidase (XO) activity and is
inhibited by SOD. Thus, inhibition activity of SOD was detected using this method.
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Briefly, serum samples and tissue homogenates were treated with WST in the
presence of the enzyme working solution in the reaction buffer for 20 mins at 37 oC.
The absorbance was read at 450 nm using a microplate reader and the percentage
inhibition rate calculated.
2.10 Assay for Reactive oxygen species production
Oxidative stress has a major role in the development of DM. Oxidative stress
in the tissues was evaluated by measuring superoxide production. Two different
methods were used: the lucigenin-enhanced chemiluminescence method for NOX
detection and the DCFH-DA method for ROS detection.
NAD(P)H-dependent lucigenin-enhanced chemiluminescence for detection
of NOX was carried out using the method of Li Y et. al. (124). Briefly, around 50 100 µg of tissue homogenates were used with 0.1 M KPi buffer (pH 7.4), and 1mM
lucigenin and 10 mM NADPH was added. Chemiluminescence was instantly
measured using the Turner Designs TD-20/20 luminometer for an integration time of
60 s. Controls were used and blank reading was subtracted from the final values
expressed.
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ROS generation was also measured by the dichlorofluorescein method using a
cell permeable probe DCFH-DA (2’, 7’-dichloro fluorescein diacetate) that measures
peroxides. DCFH-DA is a stable compound that diffuses into cells and is hydrolyzed
by intracellular esterases to produce DCFH which remains within the cells. DCFH is
rapidly oxidized by peroxy radicals to the highly fluorescent compound, 2’, 7’dichlorofluorescein (DCF). Briefly, mitochondrial samples were incubated with 5
µM of stable non-fluorescent DCFH-DA for 30 min at 37 ◦C in 0.1 M Kpi buffer, pH
7.4. The reaction was stopped using ice-cold 0.1 M Kpi buffer, containing 0.1 %
Triton X-100 and was read in a spectrofluorimeter at an excitation wavelength of 488
nm and an emission wavelength of 525 nm.
2.11 Lipid peroxidation assay
Lipid peroxidation (LPO) is the oxidative degradation of lipids. Free radicals
pull an electron from the lipids cell membrane, leading to cell damage. The LPO
assay was carried out using the LPO-586™ assay kit.
The LPO-586™ assay is based on the reaction between a chromogenic
reagent, N-methyl-2-phenylindole, and MDA and 4-hydroxyalkenals at 45 °C. One
molecule of either MDA or 4-hydroxyalkenal reacts with 2 molecules of the reagent
to produce a stable chromophore with maximal absorbance at 586 nm. Briefly, the
standards, samples and reagent were mixed followed by the addition of 37 % HCl,
incubated at 45 °C for 60mins, centrifuged and the clear supernatant read at 586 nm.
2.12 Measurement of total Glutathione sulfhydryl
Glutathione (GSH, γ-glutamylcysteinylglycine), the primary non-protein
sulfhydryl in the cells of most aerobic organisms is the body's major antioxidant
(125). It is a tripeptide, that is formed from three amino acids; glutamic acid,
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cysteine, and glycine (126).

It plays a major role in cellular metabolism. For

example, in the detoxification of certain arenes, or as a cofactor in the biosynthesis of
leukotriene and prostaglandin, it is a major antioxidant, that protects cells from free
radicals. Moreover, it is an essential electron donor to glutathione peroxidase in the
reduction of hydroperoxides (126). Glutathione is found in the reduced sulfhydryl
(GSH) and oxidized disulfide (GSSG) states. In healthy cells and tissues, it is
retained in the reduced state (GSH) by the action of glutathione reductase (127).
GSH levels were measured as protein-free sulfhdryl content using Ellman’s
reagent (128) with few modifications from the method of Tietze (127). The assay
depends on the enzymatic recycling method, via using glutathione reductase for
GSH quantification. The general thiol reagent, 5-5'-dithiobis [2-nitrobenzoic acid]
(DTNB, Ellman's Reagent) reacts with the sulfhydryl group of the GSH and
produces a yellow colored 5-thionitrobenzoic acid (TNB) and GS-TNB (between
GSH and TNB). This is then reduced by glutathione reductase and β-nicotinamide
adenine dinucleotide phosphate (β-NADPH), to produce more TNB, thus recycling
the GSH. The TNB production rate is directly related to this recycling reaction,
which is directly proportional to the concentration of GSH in the sample. TNB
absorbance measurement at 412 nm gives an accurate estimation of GSH in the
sample. The glutathione reductase reduces all oxidized GSH (GSSG) present in the
reaction mixture or formed from the mixed disulfide reaction of GSH with GSTNB to GSH. Therefore the assay measures the total glutathione in the sample.
Briefly, the reaction mixture (total volume of 1 ml) contained 143 mM NaPi/
6.3mM

EDTA,

pH

7.5,

DTNB,

20

mM

NADPH

and

30-40-

µg

cytosolic/mitochondrial protein which was precipitated with 10 % 5-sulfosalicylic
acid.
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The reaction was initiated by the addition of glutathione reductase for a
period of 2mins at 30 seconds interval. GSH amounts in the sample were estimated
by running standards of known concentration under the same conditions.
2.13 Measurement of Glutathione s-transferases activity
Glutathione S-transferases (GST), a phase ІІ detoxification enzyme exists in
different isoforms. It plays an important role in the protection against various
toxicants by catalyzing the conjugation of glutathione with the reactive electrophilic
metabolites and xenobiotics (129). Glutathione S-transferases (GSTs) can reduce
lipid hydroperoxides through their Se-independent glutathione peroxidase activity
and these enzymes have the ability to detoxify lipid peroxidation end products such
as 4-hydroxynonenal (4-HNE). Earlier studies together with results of recent studies
in our laboratory suggests that lipid peroxidation products, particularly
hydroperoxides and 4-HNE, are involved in the mechanisms of stress-mediated
signaling, and can be controlled by the alpha class GSTs through the regulation of
the intracellular concentrations of 4-HNE (130).
The cytosolic and mitochondrial GST activities were measured using 1
chloro-2, 4-dinitrobenzene (CDNB) according to the method of Habig et al. (131),
with few modifications. Briefly, the reaction mixture contained 0.3 M potassium
phosphate buffer, pH 6.5, 1.0 mM GSH, 1.0 mM CDNB, and 40-50 µg mitochondria
or cytosol. The reaction was carried out at 25°C, and the change in absorbance at
340nm was monitored for 2 mins using a spectrophotometer (model DU-70,
Beckman). All initial rates were corrected for the background non-enzymatic
reaction. One unit of activity is the formation of 1 µmol product min-1 at 25°C
(extinction coefficient at 340 nm = 9.6 mM-1 cm-1 for CDNB).
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2.14 Glutathione peroxidase activity (GSH-Px)
GSH-Px is a major antioxidant in the cellular system. It plays an important
role in the detoxification of peroxides, thereby preventing cellular lipid peroxidation.
GSH-Px uses glutathione to reduce hydrogen peroxide to water and lipid peroxides to
alcohol. Glutathione peroxidase protects cells from oxidative damage by consuming
free peroxide, in the presence of selenium as a cofactor. Considering the presence of
non-selenium enzymes, cumene hydroperoxide was used as the substrate in order to
measure the total GSH-Px (Se and non-Se enzymes) activity. This was done by
NADPH oxidation using a coupled reaction system that contains glutathione,
glutathione reductase, and cumene hydroperoxide. The reaction below demonstrates
the action of GSH-Px that oxidizes 2 moles of reduced GSH to oxidized GSSG
GR
2GSH

+

H2O2

GSSG + 2H2O2

Glutathione Reductase (GR) reduces the oxidized glutathione to complete the cycle:
GR
GSSG + NADPH + H+

2GSH +

NADP+

The oxidation of NADPH to NADP+ leads to a decreased absorbance at 340
nm. The rate of decrease in absorbance is directly proportional to the glutathione
peroxidase activity. The reaction mixture (total volume of 3 ml) contained 50 mM
KH2PO4/5 mM EDTA buffer, pH 7.0, 28 mM NADPH, 3.75 mM NaN3, 0.5 mM
GSH and 1 unit of GR that was incubated for 10 minutes at 25 ͦC before adding 50100 µg of mitochondrial or cytosolic protein. The reaction was initiated by adding
0.2 mM cumene hydroperoxide, and measured using the spectrophotometer at 340
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nm for 2-5 minutes. Results are expressed as nmol/min/mg protein, using the
extinction coefficient of NADP (6.22 mM-1 cm-1).
2.15 Assay for cytochrome P450
The cytochrome P450 enzymes form the phase ІІ detoxification enzymes,
which exists in different isoforms. They play an important role in detoxification and
protection against a wide variety of xenobiotics and various drugs. They are very
important for metabolizing many endogenous compounds and for their detoxification
(132). The CYP 2E1 isoenzyme helps in the reduction of oxygen to superoxide and
peroxide which is important in lipid peroxidation (133). The activity of CYP 2E1
was measured as described by Czygan et al. (134). Briefly, the reaction mixture
composed of assay buffer (50 mM Kpi, pH 7.4 and 10 mM MgCl2), 1 mM NADPH,
4 mM NDMA (N-nitrosodimethylamine N-demethylase), and 100-200 µg
microsomal protein were incubated at 37 ◦C for 30 minutes. 25 % ZnSO4 and
saturated Ba (OH) 2 solution were added to stop the reaction. After centrifugation, an
equal amount of NASH reagent (consisting of ammonium acetate, acetyl acetone and
acetic acid) was added to the supernatant, heated at 60 ◦C for 30 minutes and then left
to cool in ice water. CYP 2E1 activity was determined using a spectrophotometer set
at 412 nm and calculated using a standard curve plot using different concentrations
of formaldehyde run under the same conditions.
Another isoenzyme from the CYP 450 family is the CYP 3A4, which is the
most abundant enzyme found in the liver and the intestine. Similar to the CYP 2E1,
is vital in oxidizing xenobiotics, such as toxins or drugs. It plays an important role in
the metabolism of approximately half the drugs in use today. Its catalytic activity
variation is important in issues of bioavailability and drug-drug interactions (135).
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The assay of CYP 3A4 activity was similar to that of CYP 2E1, except that
erythromycin was used as the substrate for this isoenzyme.
2.16 Assay of mitochondrial respiratory complexes
Mitochondrial complexes are located in the mitochondrial inner membrane
and make up the ETC system, which plays a major role in the production of ATP, the
main energy intermediate in living organisms.
Mitochondrial complex I, also known as NADH:quinone oxidoreductase or
NADH dehydrogenase is the first enzyme (Complex I) in the mitochondrial ETC. It
works by transferring electrons from reduced Nicotinamide adenine dinucleotide
(NADH) to coenzyme Q (CoQ). This complex also translocates protons, helping to
provide the electrochemical potential involved in ATP production.

Respiratory

complex II oxidizes succinate to fumarate in the Krebs cycle and reduces ubiquinone
in the electron transport chain (136). Complex III transfers the electrons from
CoQH2 to reduce cytochrome c that is the substrate for complex IV. Complex IV,
also known as cytochrome c oxidase transfers four electrons from four molecules of
cytochrome c to molecular oxygen (O2) to produce two molecules of water (H2O).
Together, it moves four protons across the membrane, producing a proton gradient to
produce ATP.
Complex І specific activity was measured by following the decrease in
absorption due to the oxidation of NADH at 340 nm (ε = 6.81 mM-1cm-1). 0.13 mM
NADH, 65 mM ubiquinone and 2 µg/ml of antimycin were added to the assay
mixture containing 50 mM Kpi, pH 7.2 and 5 mM MgCl2 to make a final volume of
1 ml. 10-20 µg mitochondria was added and the NADH: ubiquinone oxidoreductase
activity was measured for 2 minutes, then rotenone (2 µg/ml) was added and the
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activity was measured for an additional 2 minutes. Complex І activity is the rotenone
sensitive NADH: ubiquinone oxidoreductase activity.
Complex II (succinate-ubiquinone oxidoreductase) and Complex III
(ubiquinol-cytochrome c oxidoreductase) activities were measured by monitoring the
reduction of cytochrome c at 550 nm (ε = 19.1 mM-1cm-1). 1M succinate was used
as a substrate in the assay that comprised of 50 mM KPi buffer, pH7.2, 5 mM MgCl2
and 2.5mM oxidized cytochrome c. Around 10-20 µg of mitochondrial protein was
added and the Complexes II, III activities were measured for 2 mins at 550 nm.
Rotenone (2 µg/ml) and 0.1 M sodium azide were added to block the activities of
Complex I and Complex IV respectively. The activity was expressed as nmol/mg
protein.
Complex IV activity was measured by monitoring the oxidation of reduced
cytochrome c at 550 nm (ε = 19.1 mM-1cm-1). The assay was performed using 10 µg
of mitochondrial protein at 550 nm using 50 µM cytochrome c (reduced) as the
donor. Reduced cytochrome c was prepared fresh on the same day, using 0.1 M
dithiothreitol (DTT) as a reducing agent. The assay mix contained 10 mM Tris-HCl
pH 7.0, 120 mM KCl, and 250 mM sucrose in a final volume of 1 ml. 1 mM lauryl
maltoside (LM) was added to make the external mitochondrial membrane permeable.
The initial rate of cytochrome c reduction was used to calculate the activity.
Complex IV activity is expressed as nmol /mg protein.
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2.17 Measurement of cellular adenosine triphosphate levels
Adenosine triphosphate (ATP) has many essential roles in the cells. It is the
main intermediate donor of energy needed for most of the energy-consuming
anabolic and catabolic activities in the cell. ATP is present in all metabolically
active cells. Thus it is used as a marker to evaluate cell viability. Its concentration
rapidly declines when cells undergo necrosis or apoptosis. Total cellular ATP was
measured by bioluminescence using the ATP-bioluminescent somatic cell assay kit
(Sigma, Cat # FLASC). The assay is based on the following reaction:

ATP + D-luciferin + O2

AMP+ PPi + oxyluciferin + CO2 +

light

LUCIFERASE + Mg2

The intensity of the light emitted is proportional to the amount of ATP and is
measured using a luminometer. The amount of ATP in the samples was expressed as
LU/mg protein. Briefly, 100-200 µg of mitochondrial protein were lysed with
somatic cell releasing reagent that leads the release of cellular ATP by altering
membrane permeability. The free ATP reacts with Luciferin-Luciferase in the
reaction mix and the light released was measured using a Turner Designs 20/20
luminometer. The emitted light was proportional to the ATP concentration in the
sample.
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2.18 Hexokinase assay
Hexokinase is an insulin sensitive enzyme and it is the first enzyme in the
glycolytic pathway. It uses ATP to catalyse the phosphorylation of aldo- and ketohexoses to hexose-6-phosphate. There are multiple isoenzymes of hexokinase (HK-I,
II, III and IV), they differ in their kinetic and regulatory properties and distribution in
the body. Studies have shown alterations in hexokinase in different diseases such as:
x-linked muscular dystrophy, hemolytic anemia, and cancer (137).
Hexokinase activity was measured using a hexokinase colorimetric assay kit
from Sigma –Aldrich (Cat # MAK091). The enzyme activity was determined by a
coupled enzyme assay, in which glucose was converted to glucose-6-phosphate by
hexokinase, which, in turn, was oxidized by glucose-6-phosphate dehydrogenase to
produce NADH. This, in turn, reduces a colorless probe producing a colorimetric
(450 nm) product proportional to the available hexokinase activity. The amount of
NADH produced was determined from the standard curve. One unit of hexokinase
enzyme is the amount that will produce 1.0 µmole of NADH per minute at pH 8.0 at
room temperature.
2.19 Glutamate dehydrogenase assay
Glutamate dehydrogenase (GDH) is a mitochondrial enzyme, which plays a
vital role in controlling insulin secretion. Nevertheless, it is not known if GDH
expression levels in β-cells is rate limiting for the secretory response to glucose.
GDH also plays an important role in controlling glutamine and glutamate oxidative
metabolism (138).
Abcam’s glutamate dehydrogenase kit (Cat # ab 102527) was used to detect
GDH in the mitochondrial samples. It is a sensitive method to detect the enzyme
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activity, as low as 0.01 mU. In this assay, GDH in the sample consumes glutamate
as a specific substrate and generates NADH, resulting in a proportional color
development, which is read colorimetrically at 450 nm. Briefly, the mitochondrial
samples and standards were incubated with the GDH developer and NADH for 30
mins to 2 h at 37 oC and the absorbance measured at 450 nm at 5 min intervals. The
amount of NADH generated was determined from the standard curve. 1 unit is the
amount of enzyme that will generate 1.0 umol of NADH/min at pH 7.8 and 37 oC.

2.20 SDS-PAGE and Western Blot analysis
50 µg protein from the pancreatic and heart total extract and 10-20 µg protein
from serum samples from all the four groups were separated by 10 % SDS-PAGE.
This separates the proteins according to their molecular size (139). The separated
proteins were then electrophoretically transferred to a membrane (nitrocellulose
paper) by Western Blotting (140). Membranes were blocked using 5 % non-fat milk
in TBS-0.05 % Tween-20; it is an essential step to avoid any non-specific antibody
binding. The membranes were immunoblotted with the antibodies to the proteins of
interest, as described before (141) after which the membranes were treated with a
secondary antibody for 1 hour at room temperature.

Blots were then developed

using ECL Plus Western Blotting Luminol Reagent kit(cat #), scanned and
quantitated using the ImageJ 1.48 software. β-actin was used as the loading control.
2.21 Statistical analysis
Data analysis was performed using SPSS software, version 21. All results are
expressed as means ± SEM of at least three to four determinations. Statistical
significance of the data was assessed using analysis of variance followed by LSD’s
post-hoc analysis. P values ≤0.05 were considered statistically significant.
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Chapter 3: Results

3.1 Effect of ASA on body weight
Aspirin treatment marginally lowered the body weight in control and GK rats.
The control rats which had an average weight of 325 g before treatment with ASA
showed a weight of around 295g after aspirin treatment. Similarly GK rats which
showed an average weight of around 343 g were marginally reduced to around 326 g
after ASA treatment. Although more planned studies are needed to further confirm
this observation. None the less, our study may suggest an increased utilization of
energy after aspirin treatment may be a cause of weight loss.

3.2 Effect of ASA on blood glucose and insulin levels
The fasting blood glucose level (Figure 7A) in GK rats was significantly
higher compared to control rats, and was reduced modestly (17 %) when treated with
ASA from (14.7 mM to 12.5 mM). This could be due to more efficient glucose
uptake and or utilization in ASA-treated GK rats. Similarly, blood insulin (Figure
7B) was significantly elevated (> 2-fold) in GK rats and ASA treatment significantly
reduced the levels. No significant changes in blood glucose or insulin levels were
observed in control non-diabetic rats treated with ASA. These results may suggest
increased energy expenditure in ASA-treated diabetic rats which is presumably due
to increased insulin sensitivity and responses in peripheral tissues.

56

Figure 7: Effect of aspirin treatment on blood glucose and insulin levels.
Insulin was measured in control Wistar (C) and GK rats treated with/without ASA
(n=5). Serum separated from the blood of the rats was subjected to analysis for
glucose (A) on the COBAS® INTEGRA 400 plus auto-analyzer and insulin levels
(B) were measured using the ELISA kit as described in the Materials and Methods.
Results are expressed as mean + S.E.M. from three independent experiments and
asterisks indicate significant difference. (** indicates p< 0.001 compared to
control, ∆ indicates p< 0.05 compared to GK).

3.3 Effect of aspirin on glucose tolerance
Improved glucose tolerance was observed at 60-120 mins after I.P.
administration of 2g glucose/ kg body weight in ASA treated rats. The diabetic GK
rats showed a more significant improvement (20-30 %) compared to control rats
(Figure 8). No significant alterations in glucose tolerance were observed in control
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non-diabetic rats treated with ASA. These results suggest enhanced utilization of
glucose by peripheral tissues after ASA treatment in the GK rats.

Figure 8: Effect of aspirin treatment on glucose tolerance.
Glucose tolerance test in control Wistar (C) and GK rats treated with/without
ASA (n=5). After an overnight fast, animals were injected with glucose (2g
glucose/kg body weight) intraperitoneally. Blood samples were collected from the
tail vein at time 0 (prior to the glucose load), 60 and 120 minutes after the glucose
challenge and glucose levels tested as described in the Materials and Methods.
Results are expressed as mean + S.E.M. from three independent experiments and
asterisks indicate significant difference. (* indicates p< 0.05 compared to control,
** indicates
0.001on
compared
to control, ∆ indicates p< 0.05 compared to GK).
3.4
Effect of p<
aspirin
serum biochemistry
No significant alterations in the level of total serum proteins; uric acid, ALT,
AST, LDH and CK (Figure 9A-F) was observed after ASA treatment. This suggests
that the ASA treatment had no significant toxicity in the tissues. However, a
significant decrease in triglyceride level was observed in GK rats, with no
appreciable effect after ASA treatment (Figure 10C). This may suggest increased
uptake and utilization of lipids as an initial compensatory mechanism for the lack of
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proper glucose utilization by peripheral tissues in GK rats. An increase in alkaline
phosphatase and conjugated bilirubin was also observed in GK rats which were
inhibited by ASA treatment (Figure 10D and 10E). This appears to be associated
with mild cholestasis due to hypercholesterolemia seen in these rats.

Figure 9: Effect of aspirin treatment on tissue toxicity
Tissue toxicity was measured in control Wistar (C) and GK rats. Serum separated from
the blood of the rats was subjected to analysis for total protein (A), uric acid (B),
Alanine aminotransferase (ALT) (C), Aspartate aminotransferase (AST) (D), Lactate
dehydrogenase (LDH) (E) and Creatine kinase (CK) (F) on the COBAS® INTEGRA
400 plus auto-analyzer. Results are expressed as mean + S.E.M. from three
independent experiments.
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Figure 10: Effect of aspirin treatment on blood lipid profile.
We measured cholesterol, lipoprotein, triglyceride, alanine phosphatase (ALP) and direct
bilirubin levels. Serum separated from the blood of the rats was subjected to analysis for
cholesterol (A), total lipoproteins (B), Triglycerides (C), Alkaline phosphatase (ALP) (D)
and conjugated bilirubin levels (E) on the COBAS® INTEGRA 400 plus auto-analyzer.
Results are expressed as mean + S.E.M. from three independent experiments and asterisks
indicate significant difference. (* indicates p< 0.05 compared to control, ** indicates p<
0.001 compared to control, ∆ indicates p< 0.05 compared to GK).
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3.5 Effects of aspirin on prostaglandin E2 level
GK diabetic rats showed a significant (about 2-fold) increase in Prostaglandin
E2 level indicating an increased inflammatory response (Figure 11). ASA treatment
drastically reduced the level of PGE2 both in GK diabetic and control rats.

Figure 11: Effect of aspirin treatment on Prostaglandin E2 levels.
E2 was measured in control Wistar (C) and GK rats treated with/without ASA (n=5).
Serum separated from the blood of the rats was assayed for prostaglandin E2 levels
using an ELISA kit as described in the Materials and Methods. Results are expressed
as mean + S.E.M. from three independent experiments and asterisks indicate
significant difference. (** indicates p< 0.001 compared to control, ∆∆ indicates p<
0.001 compared to GK).
3.6 Effects of aspirin on reactive oxygen species and reactive nitrogen species
A significant decrease in serum NO level was observed in GK diabetic rats
(Figure 12A). ASA treatment significantly increased the level of NO. A slight
increase in NO production was also observed in ASA treated control rats. Serum
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SOD level was significantly increased in ASA-treated GK diabetic rats but not in
ASA-treated non-diabetic control rats (Figure 12B). The increased SOD could be
due to the increased peroxide radicals, which in turn, would be converted to H2O2
and may be responsible for the increased insulin signaling. This supports our finding
of increased glucose tolerance after ASA treatment since ASA is known to play an
important role in increasing insulin sensitivity.

Figure 12: Effect of aspirin treatment on total nitric oxide and superoxide dismutase
levels. Total NO and SOD were measured in control Wistar (C) and GK rats treated
with/without ASA (n=5). Serum separated from the blood of the rats was assayed for
total NO level (A) and SOD (B) activity using the respective kits as described in the
Materials and Methods. Results are expressed as mean + S.E.M. from three
independent experiments and asterisks indicate significant difference. (* indicates p<
0.05 compared to control, ** indicates p< 0.001 compared to control, ∆ indicates p<
0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK).
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3.7 Effect of aspirin on pancreatic insulin/glucagon secretory functions
Immunoreactivity of insulin- (β) and glucagon- (alpha) secreting cells in the
pancreatic islets was checked using paraffin sections of pancreas (Figure 13). A
significant decrease in size and number of the hormone secreting cells was observed
in GK rats while ASA treatment improved the structural integrity and size of
pancreatic islets. Quantitative analysis confirmed increased pancreatic islet size
(Figure 8A) in ASA treated cells which correlated with their ability to regulate
insulin secretion confirmed by the increased percentage of insulin secreting cells
(Figure 14B) after ASA treatment. In addition, ASA treatment also enhanced the
insulin/glucagon ratio which was significantly reduced in GK diabetic rats (Figure
14C).

Figure 13: Effect of aspirin treatment on β-cell insulin/glucagon level.
Localization of insulin (green) and glucagon (red) in pancreatic islets was performed
by a double-labeled immunofluorescence method and visualized with a Carl Zeiss
fluorescent microscope as described in the Materials and Methods. Representative
islets at X40 magnification selected from at least five sets of slides from each of the
groups are shown. Bar represents 25 µm.
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Figure 14: Effect of aspirin treatment on insulin/glucagon secretion
To assess the effect of aspirin treatment, the size of the islets (A) was measured using
Axiovision® 3.0 Image Analysis System (Zeiss, Gottingen, Germany) attached to the
Carl Zeiss fluorescent microscope. Insulin- or glucagon-positive cells were counted
in visible sections at X40 magnification. The number of insulin-immunoreactive cells
was divided by the total number of cells to give the percentage of insulin secreting
cells (B). The ratio of insulin positive to glucagon positive cells was also calculated
(C). A total of 10 random islets were analyzed from a total of 5 slides in each group.
Results are expressed as mean + S.E.M. and asterisks indicate significant difference.
* indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control,
∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GKا
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3.8 Effect of aspirin on the expression of insulin
Insulin expression in the serum and pancreas of GK and control rats was also
studied by SDS-PAGE using a polyclonal antibody against insulin. An increased
expression of serum insulin was observed in GK rats confirming the insulinemia in
GK diabetic rats when compared to control non-diabetic rats (Figure 15A). ASA
treatment reduced the amount of insulin in the serum supporting the results obtained
by ELISA assay for serum insulin. These results suggest alterations in glucose
stimulated insulin synthesis after ASA treatment. Insulin expression decreased
significantly in the pancreas of GK diabetic rats. However, an increased expression
was observed after ASA treatment suggesting the recovery of β cells to produce
insulin, but the levels were still comparatively higher than that seen in control rats.
This could be because though the ASA treatment had improved glucose tolerance,
the low dose of ASA for this time period was not enough to bring the glucose levels
back to normal and thus bring the insulin levels also to control levels.

Figure 15: Effects of aspirin treatment on the expression of insulin in serum and pancreatic
homogenates.
The expression was measured in control Wistar (C) and GK rats treated with/without
ASA (n=5). Pancreatic homogenates (50 µg) and serum samples (10 µg) were
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electrophoretically transferred by 15 % SDS-PAGE and Western blot analysis to
visualize the expression of insulin (A). Β-actin was used as the loading control. The
histograms in Fig. 9B shows densitometric analysis of the protein bands and are
expressed as percentage protein compared to the control group. Asterisks indicate
significant difference. (** indicates p< 0.001 compared to control, ∆ indicates p<
0.05 compared to GK). The figures shown are representative of 3-4 independent
analyses.

3.9 Effects of aspirin on oxidative/nitrosative stress
A significant increase in mitochondrial ROS production was observed in the
pancreas (almost 80 %) and in the heart (about 50 %) of GK rats which was reduced
almost to control levels after ASA treatment (Figure 16A). Control Wistar rats
treated with ASA showed negligible ROS formation. Membrane-bound NADPH
oxidase, however, was increased only in the heart and not the pancreas of GK rats
(Figure 16B). This could suggest differential sources of ROS production the
pancreas and heart in GK rats.
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Figure 16: Effects of aspirin treatment on mitochondrial ROS and membrane-bound
NOX levels. ROS and NOX were measured in the pancreas and heart of control
Wistar and GK rats. Mitochondrial ROS production (A) in the pancreas and heart of
control Wistar and GK rats was measured using DCFDA as a probe. Total
homogenates from the tissues of these animals were analyzed for membrane-bound
NOX production using the lucigenin-enhanced chemiluminescence method as
described in the Materials and Methods. Asterisks indicate significant difference. *
indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control, ∆
indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK.The
figures shown are representative of 3-4 independent analyses.
A significant increase in pancreatic SOD and decrease in heart SOD levels
was observed (Figure 17). ASA treatment again brought back the values close to the
control. No difference was observed in the control rats treated with ASA. This
explains the increased insulin signaling by ASA treatment due to the low levels of
NO/H2O2.
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Figure 17: Effects of ASA treatment on superoxide dismutase levels.
SOD was measured in the pancreas and heart of control Wistar and GK rats.
Tissue homogenate from control Wistar and GK rat pancreas and heart was
analysed for SOD as described in the Materials and Methods. Results are
expressed as mean + S.E.M. from three independent experiments and asterisks
indicate significant difference * indicates p< 0.05 compared to control and ∆
indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK.

3.10 Effects of aspirin on lipid peroxidation
Microsomal LPO was significantly increased (about 60-70 %) in both the
pancreas and heart of GK rats (Figure 18). ASA treatment markedly reduced the
levels in both, though it was still much above the control levels. This could be due to
the increased peroxide formation suggestive of increased oxidative stress in diabetic
rat tissues.
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Figure18: Effects of aspirin treatment on lipid peroxidation in the pancreas and heart
LPO was measured in control Wistar and GK rats. NADPH-dependent LPO was
measured in the pancreas and heart of control Wistar and GK rats using the LPO kit
from Oxis Int. as described in the Materials and Methods. Asterisks indicate significant
difference. * indicates p< 0.05 compared to control. ** indicates p< 0.001 compared to
control, ∆∆ indicates p< 0.001 compared to GK. The figures shown are representative
of 3-4 independent analyses.

3.11 Effects of aspirin on GSH-dependent redox metabolism
A significant increase (about 30 %) and non-significant in the cytosolic
protein-free GSH were observed in the pancreas and heart respectively (Figure 19A).
There was no effect on the mitochondrial GSH in the pancreas though the heart
showed a slight decline in the GK animals (Figure 19B).
GSH-CDNB conjugating activity by GST enzyme in the cytosolic fraction
showed very mild alterations both in the pancreas and heart (Figure 19C). However,
the mitochondrial fraction of the pancreas showed a significant decrease in GST
activity in the GK rats and ASA treatment increased the activity (Figure 19D). This
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could be due to the increased conjugation of the GST enzyme due to the increased
mitochondrial ROS production in the pancreas. Comparatively, only a mild increase
in the activity was observed in the heart tissue, though ASA treatment seemed to
increase the activity significantly. These results suggest the differential response in
maintaining the GSH pool and its conjugating activity in the pancreas and heart of
diabetic GK animals.
Increased GSH-Px activity in the pancreas was observed both in the cytosolic
as well as the mitochondrial fractions of GK rats as well as after treatment with ASA
(Figure 19E, F). The heart, however, showed no significant alterations in the cytosol
whereas mild alterations were observed in the mitochondria. This may suggest that
the pancreas is under more oxidative stress conditions when compared to the heart
and that there seems to be more protection in the heart from increased peroxide
formation.
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Figure 19: Glutathione levels and metabolism.

GSH-Px was measured in the pancreas and heart of control Wistar and GK rats
treated with ASA

GSH concentration in the pancreas and heart of control Wistar

and GK rats was measured in the cytosol (A) and mitochondria (B) by the enzymatic
recycling method of Griffith as described in the Materials and Methods. GST
activity, using CDNB as substrate, in the pancreas and heart of control Wistar and
GK rats was measured in the cytosol (C) and mitochondria (D) as described in the
Materials and Methods. GSH-Px activity in the pancreas and heart of control Wistar
and GK rats was measured in the cytosol (E) and mitochondria (F) using cumene
hydroperoxide as substrate as described in the Materials and Methods. Asterisks
indicate significant difference * indicates p< 0.05 compared to control, ** indicates
p< 0.001 compared to control, ∆ indicates p< 0.05 compared to GK, ∆∆ indicates p<
0.001 compared to GK. The figures shown are representative of 3-4 independent
analyses.
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3.12 Effects of aspirin on CYP activities
A significant increase (60 %) in CYP 2E1 activity in the pancreas and a 35 %
increase in the heart were observed (Figure 20A). This increase in activity could be
due to increased oxidative stress. ASA treatment brought the activity to control level
in both the tissues. Similarly, CYP 3A4 activity was also significantly increased in
both the pancreas and heart (Figure 20B). However, ASA treatment could not bring
the activity back to control levels in both the tissues. In fact, the activity increased
further after ASA treatment in the heart tissue. This could be because of differential
isoenzyme expression in the heart and maybe because CYP 3A4 is involved in ASA
metabolism.

Figure 20: CYP 450 levels.
CYP 450 was measured in the pancreas and heart of control Wistar and GK rats
treated with aspirin. CYP 2E1 (A) and CYP 3A4 (B) activities in the liver and
kidney microsomal fractions were measured using standard substrates as described in
the Materials and Methods. Results are expressed as mean + S.E.M. from three
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independent experiments and asterisks indicate significant difference. * indicates p<
0.05 compared to control, ** indicates p< 0.001 compared to control, ∆ indicates p<
0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK. The figures shown
are representative of 3-4 independent analyses.
3.13 Effects of aspirin on mitochondrial bioenergetics
Respiratory Complex I activity was markedly reduced in both pancreas and
heart mitochondria of GK rats (Figure 21A). Treatment with ASA increased the
activity to almost control levels. Similarly, Complex II/III activity also was
significantly reduced in both the tissues of GK rats (Figure 21B). Treatment with
ASA again significantly increased the activity to control levels in both the pancreas
as well as the heart. However, not significant alteration in respiratory Complex IV
activity was found in either pancreas or heart (Figure 21C). On the other hand,
mitochondrial ATP levels were markedly reduced in the pancreas and heart of GK
animals (Figure 21D) though ASA treatment brought the levels to be similar to
control rats. This shows that ASA treatment has beneficial effects by increasing
energy utilization and ATP production.
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Figure 21: Effect of aspirin on the activities of mitochondrial complexes and ATP levels.
Measurement was done in the pancreas and heart of control Wistar and GK rats.
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Mitochondrial respiratory enzyme Complexes I,II/III and IV (A,B,C) activities were
measured in freshly prepared mitochondrial fractions from the pancreas and heart of
control Wistar and GK rats using enzyme specific substrates as described in the
Materials and Methods. The ATP content (D) in the rat tissues was determined using
ATP Bioluminescent cell assay kit (Sigma, St Louis, MO). Results are expressed as
mean + S.E.M. from three independent experiments and asterisks indicate significant
difference. * indicates p< 0.05 compared to control, ** indicates p< 0.001 compared
to control, ∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to
GK).

3.14 Effects of aspirin on energy metabolizing cytosolic and mitochondrial
enzymes
Glucose phosphorylation by hexokinase enzyme was significantly increased
in both pancreas and heart of GK rats (Figure 22A). ASA treatment further increased
the activity. On the other hand, activity of the mitochondrial enzyme, GDH was
significantly reduced in both the tissues of GK rats (Figure 22B). However, ASA
treatment improved the levels significantly. No change in activity was observed in
the control rats treated with ASA. These results imply improved energy utilization
and insulin responses in the pancreas and heart of GK diabetic animals after ASA
treatment.
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Figure 22: Effect of aspirin on hexokinase and glutamate dehydrogenase activities
Measurement was done in the pancreas and heart of control Wistar and GK rats.
Hexokinase (A) and glutamate dehydrogenase (B) were measured in the pancreas
and heart of control Wistar and GK rats using the respective kit protocols as
described in the Materials and Methods. Results are expressed as mean + S.E.M.
from three independent experiments and asterisks indicate significant difference. *
indicates p< 0.05 compared to control, ** indicates p< 0.001 compared to control,
∆ indicates p< 0.05 compared to GK, ∆∆ indicates p< 0.001 compared to GK.

3.15 Effects of aspirin on the expression of key redox-sensitive marker proteins
The increase in tyrosine phosphorylation of downstream insulin signaling
kinases promotes insulin signaling via the IRS1/2 signaling pathway. Increased
phosphorylation of Akt protein was observed after ASA treatment (Figure 23A) in
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the pancreas of control Wistar rats as well as GK rats. Increased phosphorylation was
also observed in the heart of control rats after ASA treatment. Significant increase in
phosphorylation of JNK protein was also observed in the pancreas and heart of both
GK and control Wistar rats (Figure 23B). Increased activation of PPAR-γ was also
observed after ASA treatment in both pancreas and heart tissues of GK rats (Figure
23C), though the increase was more significant in the heart tissues of GK rats. This
suggests an improved fatty acid metabolism after ASA treatment, thus regulating
lipid metabolism. This may also explain the reduced level of triglycerides in GK rats.
Increased carbonylation of proteins by 4-HNE conjugation was observed in
the pancreas of GK rats (Figure 23D). ASA treatment markedly decreased the level
of conjugation. The heart tissue however did not show any difference in protein
carbonylation, again suggesting increased oxidative stress in the pancreas. The heart
appears to be exhibiting extra level of redox-protection from the oxidative stress.
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Figure 23: Expression of specific marker proteins.
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Measurement was done in the pancreas and heart of control Wistar and GK rats
treated with aspirin. Homogenates (50 µg protein) from the pancreas and heart of
control Wistar and GK rats were subjected to 12 % SDS-PAGE and Western blot
analyses to visualize immunoreactivity of specific marker proteins: Akt, p-Akt
(A),JNK, p-JNK (B) and PPAR-γ and HNE (C). Beta-actin was used as loading
control. Histograms represent the ratio of the signals of phosphorylated to
unphosphorylated proteins, in (A) and (B) whereas it represents the ratio of the
protein to that of actin in (C) and are expressed as fold increase using the ratio of
control proteins as 1.0. The figures shown are representative of 2-3 independent
analyses. Molecular weights shown are in kDa.
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Chapter 4: Discussion
DM is a progressive metabolic disorder attributed to rapid economic
development and changes in life style that have led to reduced physical activity,
increased intake of refined high calorie diet and a rise in obesity (1, 3).

The

increasing incidence of diabetes, particularly T2DM, worldwide, has cost billions of
dollars in the treatment and management of this disease. T2DM is a multifactorial
metabolic syndrome associated with progressive impaired insulin secretion, insulin
response and resistance and characterized by compromised energy metabolism,
hyperglycemia, hyperlipidemia, and cardiovascular abnormalities. However, the
precise molecular mechanisms of disease progression and complications are still
unclear. The GK rat is a spontaneous non-obese animal experimental model of
T2DM. This strain was developed by selective breeding of glucose intolerant Wistar
rats over many generations. The GK rats exhibit decreased β-cell numbers and
function which is accompanied by mild hyperglycemia, impaired glucose-induced
insulin secretion, marked glucose intolerance, peripheral insulin resistance and
chronic inflammation (101-102, 142).

Despite the mild hyperglycemia several

manifestations of diabetes complications have been demonstrated in this model (143145).
Growing evidence has linked T2DM with inflammation. Thus, the GK rat
represents a good animal model for studying human T2DM pathophysiology and the
effects of therapeutic options such as the use of ASA or other NSAIDs. It is possible
that existing low-grade systemic inflammation can be suppressed by experimental
strategies aimed at blocking the production or action of proinflammatory signaling
pathways, thereby treating T2DM. There are several studies on the glycemic effects
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of salicylates and ASA (acetylated salicylic acid) in the literature, but the mechanism
of their antidiabetic effects is still unclear (106, 146). Recently, sodium salicylate
and aspirin have been shown to inhibit activation of the transcription factor NF-κB
(107) by preventing degradation of IKK-β, which regulates the inflammatory
responses, and might therefore ameliorate insulin resistance and improve glucose
tolerance in at least some patients with T2DM. However, the exact mechanism and
effects of ASA on treatment of T2DM are still not fully understood.

Salicylates have also been shown to enhance metabolic rate and energy
expenditure in GK rats (108). Recent studies on experimental rodent models of
diabetes and clinical trials have demonstrated beneficial and deleterious effects of
ASA on diabetes-associated complications and insulin sensitivity depending upon the
dose of aspirin and experimental model used (109-112, 147).
Our recent studies in diabetic rats have demonstrated that diabetes-associated
hyperglycemia caused tissue-specific increase in oxidative stress and mitochondrial
dysfunction (114,116,117,148).

Low grade systemic inflammation is considered an integral part of T2DM and
plays an important role in glycemic control (149).The GK rats are a useful model to
evaluate the mechanism of effects of ASA on disease progression. The aim of the
present study was to evaluate the potential role of aspirin and the biochemical
mechanism involved in improving glucose tolerance and insulin sensitivity in type 2
mildly diabetic GK rats. The objective was to investigate the effect of ASA on 1)
pancreatic β-cell structural integrity; 2) insulin secretion and insulinemia;3) insulin
signaling; 4) energy metabolism and mitochondrial function;5) oxidative stress and
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glutathione-dependent redox metabolism;6) drug metabolizing and detoxification
enzyme systems. We have demonstrated that low dose ASA (100 mg/Kg body wt. /
I.P.) treatment for 5 weeks reduced hyperglycemia and hyperinsulinemia with
improved glucose tolerance (utilization) by peripheral tissues without causing any
appreciable toxicity in target tissues. Improved insulin secretory function in these
rats was also observed. Our results have also suggested that insulin signaling was
improved causing an increase in energy metabolism after ASA treatment. We also
demonstrated an improvement in the drug metabolizing abilities in the pancreas and
heart of ASA-treated GK rats as suggested by the alterations in the cytochrome P450
and GSH-conjugating drug metabolizing enzymes. However, the ASA treatment
caused no significant alterations in the activities of ALT, AST, total proteins, uric
acid, LDH or CK. A mild liver toxicity was, however, observed in rats treated with
ASA. This may be due to increased cholestasis. This effect is mostly idiosyncratic
and is independent of the dose administered (150).

Insulinemia, hypercholesterolemia and hyperlipoproteinemia, in GK rats may
have caused insulin resistance resulting in hyperglycemia (149,151). Our results
have shown a marked increase in total cholesterol level in GK rats which was
significantly reduced after ASA treatment (Figure 9A). However, the cholesterol
level remains higher in GK rats treated with ASA than that seen in the control Wistar
rats. Although the individual lipoproteins were varying both in the control and GK
diabetic rats, ASA treatment caused a significant reduction in the total lipoproteins
(Figure 9B). Recent study by Wang et al. (151) also demonstrated that salacylate
treatment, in addition to a decrease in blood insulin and blood glucose levels, reduces
the levels of total cholesterol and lipoproteins. Serum triglyceride level was however

83

lower in GK rats compared to the control rats and ASA treatment had no significant
effect on the level of TG in GK rats. This may suggest increased uptake of lipids in
GK rats by peripheral tissues as a compensatory mechanism for obtaining energy
from fatty acid instead of glucose. ASA has been shown to inhibit lipogenesis in the
tissues and activate lipases to generate energy metabolizing fatty acids as a
compensatory mechanism. There are reports suggesting that ASA acts in synergy
with metformin in improving lipid metabolism and insulin sensitivity (152). ASA
treatment improves insulin sensitivity by increasing the whole body fatty acid
oxidation and by protecting the IRS from serine phosphorylation which inhibits
downstream insulin signaling (153). This effect of ASA is associated with its antiinflammatory action as well as direct activation of AMP-activated protein kinases
(154, 155).

Our results have also indicated a marked increase in serum PGE2 level in GK
rats which may have contributed to increased inflammation.

It is possible that

treatment with anti-inflammatory agent may result in reducing the proinflammatory
signals and responses in type 2 diabetes.

We have shown that ASA treatment

markedly reduced the production of PGE2 in control and GK rats. GK rats, on the
other hand showed markedly increased production of PGE2 (Figure 11). Increased
PGE2 and E-prostanoid receptors (EP2/3) negatively regulate insulin secretion and
signaling and has been linked to the pathophysiology of T2DM (156). Therefore,
inhibition of PGE2 by ASA may play a significant role in PGE2/ EP3 mediated
modulation in β-cell function and insulin signaling.
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There are reports showing that ASA increases NO production in cells and
tissues (155) and that NO plays an important role in increasing insulin sensitivity by
reducing the sensitivity of cells towards prooxidants (155-157).
NO is a freely diffusible reactive nitrogen species (RNS). Local production of
superoxide, such as within β-cells, protects the cells by scavenging NO. Low levels
of H2O2 have also been shown to induce NO production and insulin sensitivity. ASA
has been reported to protect cells from oxidative damages by stimulation of
endothelial NO production (155). There are reports that NO synthesis is reduced in
T2DMM and hypertension and that insulin regulates NO production (156, 157). We
observed that serum NO level was low in GK rats and ASA treatment increased NO
production (Figure 12A), which may have stimulated glucose tolerance and increased
insulin response. The regulation of NO metabolism in T2DM plays an important role
in insulin dependent Akt signaling and therefor disturbances of NO generation are
detrimental in insulin resistance (156). Our results show that ASA treatment appears
to have beneficial effect on the NO production in GK rat tissues.

We observed that ASA treatment increased serum SOD activity (Figure 17).
SOD converts toxic superoxides to H2O2 and thus may help in H2O2-dependent
insulin signaling and increased glucose transport in target cells. Insulin signaling is
reported to be positively and negatively affected by ROS production. At a low
physiological level, H2O2 is involved in enhancing insulin signaling by activating
insulin receptor-tyrosine kinase activity and engaging the IRS-1/PI3k/AKTdependent downward signaling to increase basal glucose transport activity (158). At
lower concentrations, H2O2 has been reported to mimic insulin signaling even in the
absence or low levels of insulin and inhibits PTP1B activity to prolong insulin
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receptor tyrosine kinase activity. In contrast, in the presence of insulin, H2O2 inhibits
insulin signaling by activating deleterious serine/threonine kinases developing
insulin resistance (159, 160). Persistent hyperglycemia and insulinemia, systemic and
islet inflammation and increased ROS are all involved in developing insulin
resistance and β cells structural and functional defects in T2DM (161, 163). Clinical
and experimental trials have validated the beneficial effects of anti-inflammatory
therapies including ASA treatment (149, 151, 162, 164). Emerging results suggest
that both β cell mass and abnormal secretory functions are implicated in T2DM (165,
166). As shown in our immunofluorescence study (Figure 13), ASA treatment has
improved both the structural and functional properties of β islets. This may be
associated with the anti-inflammatory property of ASA which helps in regenerating
functional β cells, glucose stimulated insulin secretion, insulin sensitivity, glucose
transport and energy utilization in T2DM.

In diabetes, hyperglycemia and hyperlipidemia are associated with increased
ROS production and oxidative stress (115, 167, 168, 169, 170).

Excessive

superoxide production, however, either by NOX or mitochondrial respiration may
result in excessive formation of peroxynitrite a highly reactive nitrogen species,
which may accelerate the deleterious metabolic complications in diabetes. Using
both type 1 and type 2 diabetes rat models we have shown the excessive production
of ROS, increased oxidative stress associated mitochondrial and metabolic stress in
the tissues (114- 117, 148). Our present study on GK diabetic rats has also exhibited
an increased oxidative stress related metabolic changes and mitochondrial
dysfunction in the pancreas and heart. ASA treatment however had some beneficial
effects. As shown by SDS-PAGE analysis, the increased carbonylation by 4-HNE-
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conjugation of oxidized proteins was observed in GK rat tissues. ASA treatment
decreased the oxidative 4-HNE-conjugation of proteins. GK rats pancreatic β-cells
have been shown to be oxidatively stressed and have high-HNE-modified proteins
(161). ASA appears to be protecting the mitochondrial proteins from oxidative
carbonylation thus preventing mitochondrial dysfunction which is linked to develop
insulin resistance in the tissues (171).

Our SDS-PAGE analysis (Figure 23) also revealed that ASA treatment
increased AKT and JNK phosphorylation which promotes insulin signaling via
activation of IRS1/2 and insulin-dependent downstream signaling. ASA treatment
has also been shown to inhibit serine phosphorylation of IRS as seen in inflammatory
responses, thereby stimulating the tyrosine phosphorylation of IRS through AKT
pathways resulting in increased insulin sensitivity. The effect is associated with the
anti-inflammatory action of ASA (153, 154, 172, 173). Activation of PPAR-ϒ in the
pancreas and heart tissues after ASA treatment also suggests an improved fatty acid
metabolism in GK rats treated with ASA. PPAR-ϒ family of nuclear receptors play
an important role in the regulation of lipid metabolism by stimulating the genes
involved in the lipid uptake and adipocytes differentiation. PPAR-ϒ agonists of the
thiazolidine (TZD) family are being extensively used for the treatment of T2DM due
to their insulin sensitizing properties. Increased expression of this protein in the
tissues of GK rats after ASA treatment suggests another mechanism of improving
insulin responses by ASA treatment (174). Another mechanism proposed by TZD is
that it inhibits mitochondrial respiratory complexes in mitochondria, like metformin,
and pyruvate carrier resulting in the activation of AMPK which facilitates
mitochondrial biogenesis and hence insulin responsive increase in energy utilization
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(175, 176). Our results on GK rats also support these observations and add a
mechanistic explanation of ASA action in improving T2DM.

Mitochondrial oxygen /energy metabolism to generate ATP via oxidative
phosphorylation is also accompanied by ROS production. Mitochondria generate
moderate levels of ROS during normal oxygen metabolism in oxidative
phosphorylation during the metabolism of glucose and fatty acids. The low level of
ROS enhances insulin sensitivity upon redox regulation of insulin receptor (tyrosine
kinase) and substrates (IRS family). However, chronic exposure to high levels of
ROS produced in T2DM could alter the mitochondrial function and thereby cause
insulin resistance. Our results on GK rats have shown a compromised mitochondrial
respiratory function with altered enzyme activities of inner membrane respiratory
complexes (Figure 21). These results confirm our previous observations on STZinduced diabetes or on Zucker type 2 fatty rat tissues (114-117, 148). ASA treatment
seems to have beneficial effects by altering the mitochondrial functions in favor of
energy metabolism and improved insulin signaling as observed by increase glucose
phosphorylation by hexokinase and by increasing the activity of glutamate
dehydrogenase (GDH) which generates alpha-ketoglutarate, an intermediate of
tricarboxylic acid cycle. Activation of GDH has been associated with increased
insulin secretion and energy metabolism (177, 178).
We have also observed that ASA treatment not only affected the
mitochondrial function and oxidative stress but also involved in regulating GSHdependent antioxidant homeostasis as well as CYP-dependent metabolism in the
pancreas and heart of GK rats. The CYP 2E1 activity was increased in GK diabetic
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rats suggesting the ROS mediated oxidative and metabolic stress (Figure 14A) (114117, 148). ASA treatment resulted in the reduction of CYP activity. Similarly, CYP
3A4 activity was also affected by ASA treatment suggesting the adaptation of
metabolic stress in GK rats (Figure 20B). This may also suggest a differential
isoenzyme specific metabolism of ASA in the pancreas and heart. GSH-antioxidant
pool as well as GST enzyme which conjugates endogenous oxidants such as HNE
and other lipid peroxides was also altered after ASA treatment. These results have
confirmed our previous observation (114-117, 148, 179) of altered drug metabolism
in diabetes.

ASA appears to have some adaptation in improving the drug

metabolizing abilities of the tissues.
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Chapter 5: Conclusion

With more than 350 million estimated global cases, diabetes is a pandemic
disease with increasing morbidity and mortality. In the absence of an appropriate
prevention and poor management, the current predictions for diabetes prevalence
could double by 2035. Approximately 90 % of diabetics have T2DM with multiple
etiological bases. While intervention by life style management and dietary control is
an acceptable strategy to control energy metabolism, it is difficult to adhere to
lifestyle changes for a long period of time. Moreover, the efficacy of current antidiabetic drugs is limited with unwanted side effects. Consequently there is a need
and demand for the development of safer and more effective drugs in type 2 diabetes.
Therefore, it is important to understand the mechanisms involved in the etiology and
pathophysiology and progression of insulin resistant T2DM and to identify the key
molecular targets for anti-diabetic therapeutics. Chronic hyperinsulinemia,
glucotoxicity and lipotoxicity have been identified as the major causes of insulin
resistance and diabetes-associated complications. The onset of diabetes may start
with pancreatic β-cell structural and functional defects, insulin secretion and glucose
stimulated insulin release, insulin circulation and insulin signaling. The progression
of the disease due to excessive availability of glucose and fatty acids include insulininsensitivity in target tissues. Additionally, mitochondrial dysfunction with reduced
fatty acid and energy metabolism may result in increased ROS production and
oxidative stress with compromised redox-homeostasis resulting in the deterioration
of the structural and functional integrity of tissues. The most common features are
progressive metabolic syndrome with diabetic-induced retinopathy, neuropathy and
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nephropathy. Mitochondrial dysfunction is considered to be an important cause of
insulin resistance with compromised energy utilization.
ASA has been around for a long time for the treatment of cardiovascular
diseases. In 2007, the ADA and AHA jointly recommended that ASA (75 to 162
mg/day), to be used as a primary preventive drug in T2DM patients with increased
cardiovascular risks (180). However, there are conflicting reports and disagreement
regarding the use of ASA for primary prevention in diabetes (181). Moreover,
measuring the response to ASA is often difficult as some patients may show ASA
resistance. Furthermore, there are other potential factors which may affect ASA
efficacy in patients which include: ASA dose, disease severity, genetics, obesity and
inflammation, smoking and complications of the disease and interactions with other
drugs.
The objective of the present study was to further investigate the mechanism
of ASA action on young GK diabetic-insulin resistant rats using an accepted
effective dose based on the literature search and injecting the drug intraperitoneally
(I.P.) to avoid gastric toxicity caused by ASA. Our hypothesis was; 1) to elucidate
the mechanism of ASA action on pancreatic β-cell structure and insulin secretion; 2)
study the effect of ASA on insulinemia and hyperglycemia/dyslipidemia; 3) to study
the effect of ASA on glucose tolerance;4) to study the effect of ASA on insulin
signaling; 5) to study the effect of ASA on energy metabolism; 6) to study the effect
of ASA on mitochondrial functions and oxidative stress and 7) to study the effect of
ASA on drug metabolism. Our results suggest that ASA has improved β-cells
integrity and insulin secretory function. We have also shown that ASA treatment to
GK rats has improved glucose tolerance, insulin signaling based on Akt/JNK
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phosphorylations and energy metabolism with improved glucose and lipid
metabolism in the pancreas and heart. ASA treatment also altered oxidative stress,
mitochondrial function and redox homeostasis which may have consequences in
developing insulin-sensitivity in diabetes.
Further studies are needed to study the mechanism of ASA action using
different doses and routes of administration along with clinically approved antidiabetic drugs. Also, we need to elucidate the effect of ASA on energy metabolism,
mitochondrial function, oxidative stress, insulin signaling response in different
tissues from young and chronic diabetic rats. Identification of molecular targets for
downstream insulin signaling affecting the energy (glucose and fatty acids)
metabolism in GK rats will highlight the efficacy of ASA alone or in combination
with clinically approved anti-diabetic drugs in type 2 diabetic animal models. Our
study might be helpful in designing strategies for the therapeutic management of
insulin-resistant T2DM.
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